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GENOTYPIC CONFIRMATION OF TRANSIMMUNIZATION-INDUCED 
DENDRITIC CELL MATURATION 
Kristin E. Hoffmann, Gabriel Vasquez, Carole L. Berger, Michael Girardi, Robert Tigelaar, and 
Richard L. Edelson.  Department of Dermatology, Yale University School of Medicine, New 
Haven, CT. 
 
Transimmunization (TI), a novel modification of the widely used immunotherapy extracorporeal 
photopheresis (ECP), induces conversion of processed monocytes into cells expressing 
phenotypic and functional features of dendritic antigen presenting cells (DC).  To further 
characterize TI-induced DC, we analyzed differential gene expression in the monocyte/DC 
population after TI treatment.  Because ECP, the therapy upon which TI is based, has the unique 
capacity to induce both anti-cancer immune responses in cutaneous T cell lymphoma (CTCL) 
patients and tolerogenic responses in graft-versus-host disease (GVHD), we studied TI-induced 
gene expression changes in both of these patient populations as well as in healthy normal control 
individuals with the goal of fully characterizing the gene expression profile(s) induced by TI.  
Peripheral blood leukocytes from 6 patients (3 patients with CTCL and 3 patients with GVHD) 
were procured prior to ECP, immediately after ECP, and following TI processing, and were then 
enriched for monocytes/DC.  RNA was extracted and gene expression compared using 
Affymetrix total human genome microarrays to analyze 39,000 genes.  Differential gene 
expression was considered as a ≥ 2-fold change and P-value ≤0.05.  TI induced significant up-
regulation of genes associated with DC maturation including: DC-LAMP, CD80, CD40, and 
Decysin.  In addition, TI induced down-regulation of monocyte genes such as CD33 and CD36.  
These changes in gene expression were seen in both CTCL and GVHD patients, suggesting that 
TI is capable of mediating DC differentiation regardless of disease process.  However, some 
genes (e.g. IL-19, Tryptophan 2,3-dioxygenase) were differentially expressed after TI only in 
GVHD patients, while others, (e.g. heat-shock proteins 70, 27, and 40) were differentially 
expressed only in CTCL patients.  Our microarray findings were confirmed by quantitative real-
time PCR on patient samples as well as on samples from healthy normal controls that underwent 
the TI procedure.  Analysis of the microarray data using GeneGo pathway analysis software 
demonstrated that the chemokines and adhesion signaling pathway was significantly involved in 
the mechanism of both ECP and TI, suggesting a crucial role for cell adhesion in these therapies.  
Taken together, our gene expression and pathway data suggest that TI activates specific signaling 
cascades that lead to activation and up-regulation of mature DC genes.  Our results support the 




First and foremost, I would like to thank my advisors Dr. Carole Berger and Dr. Richard 
Edelson.  Words can simply not express how grateful I am for all you have done for me 
and how fortunate I feel to have been a part of your research program.  Dr. Edelson, your 
enthusiasm and energy are contagious, and your ability to inspire others is truly 
remarkable.  I hope one day to be able to inspire in others even the smallest amount of 
hope and purpose you have inspired in me.  Your insightful comments, constant 
encouragement, and wonderfully entertaining stories and advice about science, medicine, 
and life have been a true highlight of this year.  It has been an experience I will carry with 
me for the rest of my life and one that I am confident will shape my future career. 
 
The person most responsible for my accomplishments and personal growth throughout 
my time in lab is Dr. Carole Berger.  I am so grateful I have had the opportunity to 
interact with such a wonderful mentor, outstanding scientist, and truly caring person on a 
daily basis for the past year and a half. Your guidance and dedication are the reason I 
have been able to accomplish the work presented here.  You are a superb mentor and also 
a wonderful friend- any time I had a question or idea your door was open and you were 
willing to help.  Thank you for all of your fantastic advice, about science and also about 
life.  I am so grateful for all you have done for me- you have truly been the best advisor a 
student could ask for. 
 
A huge thanks to fellow lab members Dr. Gabe Vasquez, Nianci Wang, and Zimei 
Zhang.  Thank you for all of your help and also for your excellent camaraderie and 
companionship- you have made my experience in lab such a positive and enjoyable one.   
 
Thank you to Dr. Tigelaar and Dr. Girardi for their scientific guidance and advice.  Also 
thank you for agreeing to be on my thesis committee and for your help with this 
document.  I have the utmost respect for both of you as careful and thoughtful scientists 
and I am extremely grateful for your input on this work.   
 
Thank you to all of the Yale Photopheresis patients who donated samples of their 
photopheresis treatments so that we could accomplish this project.  Your sense of hope 
has been energizing and truly humbling.  My proudest accomplishment would be if this 
work would ultimately benefit you and others with your disease. 
 
I would also like to acknowledge research support from the NIH T32 Clinical Research 
Fellowship and the New York Cardiac Center.  These funds, along with additional 
funding for laboratory supplies and microarray experiments from the Yale SPORE, made 
this project possible. 
 
Last but certainly not least, thank you to my family and friends.  Thank you Hristos for 
your endless encouragement and support.  Thank you to Claire and Natalie, the best 
sisters in the entire world, for always being able to make me laugh and for your countless 
encouraging words- you are the best!   Thank you to my parents for being a constant 
source of encouragement, moral support, and above all, inspiration.  
 
Table of Contents 
Introduction……………………………………………………………………………... 1 
Statement of Purpose………………………………...………………………………… 12 







Extracorporeal photopheresis (ECP) is a novel immunomodulatory therapy that 
was initially developed to treat cutaneous T cell lymphoma (CTCL).  This therapy holds 
the distinction of being the first FDA-approved selective immunotherapy for cancer, 
having obtained an expedited approval in 1988 because of its impressive clinical efficacy.  
Over the past 20 years ECP has been administered over 250,000 times at roughly 150 
treatment centers throughout the USA and Europe (1).  Not only is this therapy effective, 
it also has an excellent safety profile with no limiting toxicity and remarkably few 
adverse reactions (2).  Since the inception of ECP in the early 1980s, its success has been 
driven by clinical results.  The initial report on ECP, published in the New England 
Journal of Medicine in 1987, described the effects of ECP treatment on 37 patients with 
otherwise resistant CTCL.  27 of these patients responded to ECP, with an average 64% 
decrease in cutaneous involvement (3).  Two patients with severe erythrodermic CTCL 
experienced complete remissions in response to ECP, a provocative result because 
spontaneous remissions do not occur in this type of CTCL, indicating the remissions were 
due to ECP (4). 
 
The rich history of the development of ECP starts with the curiosity of Dr. 
Richard Edelson, a dermatologist then at Columbia University.  Dr. Edelson played a 
large role in the research characterizing CTCL, a clonal expansion of skin-associated 
CD4+ helper T cells (5).  In early stages of the disease, the malignant cells are confined 
to the epidermis in patches and plaques (5).  In more aggressive cases of CTCL the 
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malignant CD4+ cells can spread throughout the skin and also to the blood, causing 
diffuse erythroderma and severe leukemic disease (6).  A common treatment for plaque-
stage CTCL is PUVA therapy (P, psoralen and UVA, ultraviolet light).  In this therapy, 
orally administered 8-methoxypsoralen (8-MOP) is photoactivated by exposure of 
diseased skin to ultraviolet A.  When activated, 8-MOP is transformed to a transiently 
excited state, in which it is capable of covalently cross-linking DNA (7). Importantly, in 
its biologically inert state 8-MOP is completely safe and is excreted from the body in 24 
hours, making it a unique chemotherapeutic agent.  Dr. Edelson saw that PUVA therapy 
offered plaque-stage CTCL patients an effective treatment with few side effects, and he 
speculated whether a variation of this therapy could somehow be used to treat CTCL 
patients with more severe disease, especially those in whom the malignant CD4+ cells 
had spread to the blood.  At the time, patients with the erythrodermic and leukemic phase 
of CTCL were commonly resistant to chemotherapy and had a survival of less than 30 
months (3).  In some patients, intensive leukapheresis (removal of blood leukocytes) was 
effective in slowing the disease course (3).  Armed with the knowledge of the 
effectiveness and safety of PUVA and the experience in using leukapheresis, Dr. Edelson 
and colleagues conceived a completely novel therapy, which they termed Extracorporeal 
Photopheresis.  This therapy involved administering oral 8-methoxypsoralen to the 
patient and then performing a leukapheresis step, collecting the patient’s white blood 
cells and plasma.  The 8-MOP treated white blood cells and plasma were then passed 
through thin plastic tubing sandwiched between UVA lights, activating the 8-MOP.  
After treating the patient’s leukocytes with 8-MOP + UVA, the treated cells were 
returned back to the patient.  The original goal of ECP was simply to induce cell death in 
3 
 
the treated malignant CD4+ cells.  However, Edelson and colleagues observed that this 
therapy induced a much greater anti-cancer response than simply causing apoptosis of 
treated cells.  Since only 5% of malignant cells pass through the ECP apparatus during 
each treatment procedure, the fact that ECP induced full remissions in a subset of patients 
and partial remissions in others (with an average 64% decrease in cutaneous 
involvement) implied that ECP was capable of inducing a systemic anticancer response.  
Edelson and colleagues set out to learn more about the mysterious mechanism of ECP, 
asking how a therapy that only treats a fraction of malignant cells produces such 
profound clinical effects. 
 
There were several important clinical observations and scientific findings that 
lead to an understanding of the cellular mechanism of ECP.  First, it was observed that 
the best responders to ECP were patients that had a relatively intact immune system, 
reflected as a near normal CD4:CD8 ratio, before beginning therapy (8).  These patients 
had robust numbers of CD8+ cytotoxic T lymphocytes, the cell type capable of 
recognizing cellular antigen in the context of MHC class I and then inducing death in 
target cells (9).  At the time ECP was introduced, scientists had recently discovered that 
CD8+ T cells could recognize tumor antigens and cause tumor cell death (9).  Since an 
intact CD8+ T cell compartment seemed critical for a successful clinical response to 
ECP, Dr. Edelson and colleagues became interested in how ECP affected CD8+ T cells.   
 
The crucial piece of information came from studies examining apoptotic cell 
death after ECP.  Yoo and colleagues found that ECP induced apoptosis in all peripheral 
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blood T cell subpopulations, including the malignant CD4+ T cells.  However, the 
monocyte population did not undergo apoptosis after ECP (10).  In fact, instead of dying, 
the monocytes (normally responsible for surveying the cellular environment and 
ingesting potential antigenic material) were observed phagocytosing the ECP-treated 
apoptotic cells.  Monocytes may serve as precursors to dendritic cells, or antigen 
presenting cells, which play a crucial role in the immune system.  Dendritic cells (DC) 
display antigen in the context of MHC molecules for recognition by lymphocytes (9).  
Fascinated that monocytes were resistant to ECP-mediated apoptosis, Berger and 
colleagues set out to characterize ECP-treated monocytes.  Their results showed that ECP 
treatment activated monocytes and initiated their differentiation into DC (11).  These 
ECP-induced DC actively phagocytose apoptotic lymphocytes, process cellular antigen, 
and present tumor-specific CTCL antigens on MHC molecules (12).  When CTCL 
antigens are presented in the context of MHC I molecules, they can be recognized by 
cytotoxic CD8+ T cells, and these cells are capable of mediating an anti-tumor immune 
response (13).  The fact that patients with a relatively normal CD8+ T cell compartment 
respond best to therapy supports the idea that ECP-induced DC are stimulating a CD8+ T 
cell response against CTCL cells. 
 
An important link between ECP-induced apoptosis and initiation of an anti-tumor 
CD8+ T cell response is likely the presentation of tumor antigen by dendritic cells (11).  
The fact that ECP induces monocyte to DC differentiation is extremely important and 
makes ECP a powerful immunotherapy.  In considering how monocyte activation occurs 
during ECP, one hypothesis has been that the passage of monocytes through the thin (1 
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mm thick) plastic UVA exposure plate induces DC differentiation.  Monocytes are 
known to adhere to plastic, activating cell adhesion molecules and downstream signaling 
cascades (14).  The flow turbulence and sheering forces in the ECP apparatus likely 
create a situation where the monocytes repetitively adhere and disadhere to the plastic 
surface, amplifying cellular signals and leading to monocyte activation (12). 
 
As researchers worked to uncover the mechanism underlying ECP, the clinical 
use of this therapy dramatically accelerated.  The initial report published in 1987 by 
Edelson and colleagues demonstrated a 64% response rate and inspired many clinicians 
to use ECP to treat refractory CTCL.  Data published on more than 500 CTCL patients 
receiving ECP at centers around the world confirmed the impressive initial clinical 
findings of Edelson, with an average overall response rate of 62% and an average 20% 
complete response rate (4).  In addition, a follow-up study in which ECP was compared 
with historical controls demonstrated that ECP increased survival time from 30 months to 
more than 66 months (15).   
 
Since CTCL is characterized by a clonal population of T cells and ECP appeared 
to have selective effects on this pathogenic T cell population, clinicians began to evaluate 
the use of ECP to treat other T cell mediated diseases (4).  ECP has been tested in a 
variety of nonmalignant immune-mediated diseases, such as systemic sclerosis, 
pemphigus vulgaris, rheumatoid arthritis, psoriatic arthritis, systemic lupus erthematosus, 
and to a lesser extent atopic dermatitis and inflammatory bowel disease (4).  In addition, 
ECP has been used to treat acute and chronic organ transplant rejection and graft versus 
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host disease (GVHD) after allogeneic bone marrow transplantation.  In a review of 184 
cases of chronic GVHD treated with ECP, the response rates were as follows: skin (75% 
response), liver (66% response), lung (25% response), gut (18% response) and mucous 
membranes (68% response) (16).  The response rates for acute GVHD were 58% in skin 
and 40% in liver (16).  In the majority of patients with GVHD, concurrent 
immunosuppression could be reduced during ECP and no increase in opportunistic 
infections was reported (16).  A trial testing ECP for the prevention of rejection in cardiac 
transplantation, published in the New England Journal of Medicine, found that ECP 
significantly decreased the risk of cardiac rejection without increasing the incidence of 
infection (17).  ECP has subsequently been used to treat lung and renal transplant 
rejection in a small number of patients and has been reported to be of benefit (18, 19).   
The fact that ECP has a dose-sparing effect on concurrent immunosuppressive therapy is 
important for GVHD and organ transplant rejection patients because it may spare these 
patients, who often are on multiple immunosuppressive agents, some of the adverse 
effects associated with long-term immunosuppression.  The growing acceptance of ECP 
for transplant rejection is evidenced by the use of ECP as part of the anti-rejection 
regimen in the recent high-profile French face transplant (20).  This patient received 
treatment with the French version of ECP, which uses a slightly different apparatus than 
the Therakos machine used here in the United States.  In France, a “two independent 
steps” technique is used, in which the first step consists of mononuclear cell collection by 
a continuous blood cell separator, and then irradiation of collected cells is performed 





The fact ECP appears to be able to generate selective immunosuppression in 
various autoimmune and alloimmune disorders has generated interest among researchers, 
particularly because in CTCL patients this same therapy appears to generate a selective 
anti-tumor immune response (22).  How could ECP generate tolerance in some patients 
and an anti-tumor immune response in others?  The answer may lie in the ability of ECP 
to initiate monocyte to dendritic cell differentiation, for the simple reason that dendritic 
cells control T cell responses.  DC are capable of mediating such diverse, contradictory 
functions as anti-tumor immune responses and tolerance depending on the signals they 
send to T cells as they present antigen (23).  It is thought that DC can “decode” 
environmental signals, and depending on the presence or absence of certain inflammatory 
or “danger” signals present at the time they are capturing and processing antigen, develop 
into either DC capable of stimulating T cell responses or DC that induce tolerance (23).  
With this in mind, it is important to mention that in ECP therapy the environment in 
which newly differentiating DC capture antigen (apoptotic cells) is in the patient.  
Because 8-MOP + UVA induces a gradual apoptosis, the lymphocytes do not die during 
the ECP procedure itself (which takes about 3 hours), but instead undergo apoptosis after 
they are reinfused into the patient (11).  The presence or absence of various forms of 
inflammatory stimuli in the patient may therefore play a crucial role in whether the 
induced DC are immunogenic or tolerogenic.  In addition, because the disease processes 
and immune state of CTCL and GVHD patients are so different, it is possible that the 
environment from which the DC precursors come may influence their subsequent 




Focusing in on the success of ECP in treating CTCL patients in combination with 
the new scientific knowledge about ECP inducing monocyte to DC differentiation, a 
group of researchers led by Drs. Edelson and Berger set out to logically modify the 
existing ECP procedure in order to improve its efficacy as an anti-cancer treatment.  This 
modification of ECP involves overnight incubation of the treated cells, allowing for more 
efficient cell-to-cell contact and processing of the apoptotic malignant T cells by newly 
formed DC, further driving monocyte to DC differentiation and increasing the yield of 
DC produced by the procedure (11).  Cells undergo the ECP procedure and are then 
incubated overnight and returned to the patient the next day.  This new methodology, 
called Transimmunization (TI) to denote the transfer of immunogens from tumor cells to 
antigen-presenting cells (DC), has a significant therapeutic impact.  In a phase I trial, 
CTCL patients that had previously failed ECP sustained clinical responses after TI 
treatment (24).  TI is potentially a more potent anti-cancer immunotherapy because the 
activated monocytes are more fully differentiated into DC when they are reinfused into 
patients, and such DC are more potent antigen presenting cells (23).   
 
The maturity state of DC used for immunotherapy is thought to play an important 
role in therapeutic efficacy.  It has been hypothesized that whether DC will induce 
immunity or tolerance largely depends on the degree of maturation they reach (25).  In 
the presence of inflammatory signals DC will become mature and stimulate the immune 
system, whereas in the absence of such signals they will remain in an immature state and 
induce tolerance (25).  Therefore, many current approaches for generating DC for cancer 
immunotherapy include the addition of maturation stimuli.  However, the risk of inducing 
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exogenous maturation stimuli is that excessive stimulation during ex vivo cell 
manipulations may exhaust DC and also reduce their capacity to capture antigen (26).  
Obtaining the appropriate culture conditions for DC maturation is difficult- the amount 
and timing of the maturation stimulus must be exact in order to generate effective DC 
(25).  In fact, this is just one of the many challenges facing researchers who are 
attempting to manufacture DC-based anti-tumor immunotherapies.  There are many 
variables in the design and production of DC vaccines, including selecting the type of 
tumor antigen(s) for DC loading, determining the DC culture and maturation steps (e.g. 
the cytokine cocktail used to achieve maturation and length of culture, typically 1-2 
weeks), deciding on the use of co-stimulatory molecules for DC activation ex vivo, and 
choosing methods to monitor the DC potency (27).  Despite careful manipulation of these 
variables, to date there has been limited success using DC-tumor vaccination, with the 
majority of tumor vaccines having inconclusive efficacy results (27). 
 
Compared to other procedures for generating DC for tumor immunotherapy, TI is 
efficient and straightforward.  In TI, apoptotic tumor cells supply the full array of tumor 
antigens, eliminating the need to identify and select specific tumor antigens to load onto 
DC.  The culture conditions are simple in TI: the ECP-treated cells are incubated 
overnight without the addition of exogenous factors.  Other methods for generating DC 
involve culture for at least 5-7 days in high concentrations of exogenous cytokines.  It 
does not appear necessary to use exogenous factors or co-stimulatory molecules for DC 
activation in TI.  Instead, the DC are activated in a physiologic manner in which the 
attachment to plastic and subsequent activation of cell surface receptors may replicate 
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signaling events that occur in vivo as monocytes emigrate from the blood into peripheral 
tissues, which involves adhesion and activation of surface receptors such as chemokine 
receptors and integrins (28).  This is followed by incubation with an additional 
maturation stimulus in the form of stressed, apoptotic tumor cells which provide “danger 
signals” and enhance DC immunostimulatory function (29).  TI-induced DC are 
particularly appealing because they can be generated rapidly (in 24 hours).  TI holds the 
potential to be a widely used immunotherapy, and the full characterization of TI-induced 
DC is essential to building upon its efficacy and clinical use.   
 
In addition to characterizing TI-induced DC at the cellular level, elucidating the 
underlying mechanism of DC activation and differentiation is important for guiding 
modifications that may increase treatment efficacy, and also to determine if the therapy 
might be applicable to other cancers or immunologic diseases.  One method that is widely 
used to study cellular mechanisms, including the mechanism of DC differentiation, is 
expression microarray technology (30).  Microarray technology is a powerful means for 
systematically and extensively assessing entire transcriptomes, providing clues as to what 
cellular processes and signaling pathways are involved (24).  We used Affymetrix 
expression microarray technology to gain insight into the mechanism of TI.  Affymetrix 
GeneChips are one of the best established microarray platforms, and are known to 
generate highly reproducible results (25).  Affymetrix microarrays consist of small DNA 
fragments bound to a glass surface.  These fragments are short (25-mer) oligonucleotides, 
and there are up to 20 perfect match oligos for each gene, as well as an equal number of 
corresponding mismatch oligos.  By extracting and labeling RNA from samples and 
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hybridizing this RNA to gene expression arrays, the amount of labeled RNA can be 
monitored at the site of each oligo, enabling whole-genome analysis of gene expression.    
 
Our microarray analysis of differential gene expression after ECP and TI 
demonstrates that TI induces a gene expression profile consistent with mature DC. 
Importantly, this monocyte to DC conversion is not just seen in CTCL patient samples, 
but also in samples from patients with graft-versus-host disease and from healthy normal 
control samples, indicating that the conversion into mature DC is generalizable and not 
unique to CTCL patients.  TI is safe, clinically practical, and has a distinct advantage 
over ECP in that it produces greater numbers of DC that are further differentiated down 
the pathway to mature DC.  In addition, TI has an advantage over other widely used DC 
maturation protocols in that it rapidly induces mature, tumor-loaded DC without the 
addition of exogenous cytokines.  TI has a proven track record in terms of safety, and it 
may provide an answer to many of the problems with other forms of DC immunotherapy.  
Our hope is that understanding the mechanism of TI will lead to an optimization and 
broadening of the scope of this therapy.   
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Statement of purpose 
 
Our purpose was to characterize the mechanism by which Transimmunization, an 
immunotherapy wherein leukocytes treated with extracorporeal photopheresis are 
incubated overnight, induces dendritic cell differentiation and regulates immune 
responses through the analysis of differential gene expression.  Using expression 
microarray technology, we performed genome wide analysis of samples taken from 
patients undergoing these immunotherapies.  Previous work has shown that monocytes 
treated with Transimmunization express phenotypic and functional characteristics of 
activated dendritic cells.  Therefore, we hypothesized that Transimmunization would 
induce differential expression of genes involved in monocyte to dendritic cell 
differentiation.  Identification of the gene expression signature induced by this therapy 
may elucidate the mechanism(s) of Transimmunization-induced dendritic cell activation 
through the identification of key signaling pathways or novel genes. 
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Materials and Methods 
Patient samples 
Peripheral blood leukocytes from patients undergoing ECP using the Uvar XTS 
Photopheresis System (Therakos, Exton, Pa., USA) were obtained under the guidelines of 
the Yale Human Investigational Review Board.  Informed consent was provided 
according to the Declaration of Helsinki.  Samples (10 ml) were procured from 1) a 
leukocyte enriched leukapheresis sample taken from the photopheresis apparatus 
collection bag immediately before 8-MOP is added; and 2) an ECP specimen taken 
immediately post UVA exposure.  This ECP sample was divided and half of the sample 
was cultured overnight, mimicking transimmunization.  For a select group of patients we 
also took a 5 ml sample of untreated whole blood, drawn directly from the patient prior to 
treatment.  It should be mentioned that the leukocyte enriched leukapheresis sample taken 
from patients undergoing treatment is drawn from the Uvar XTS Photopheresis System, 
and by the nature of this system the leukapheresis flows through the plastic exposure 
plate first before flowing into the collection bag.  Therefore, this sample does not meet 
the classical definition of a leukapheresis.  However, because it has only undergone 
transient exposure to the plastic treatment plate and has not been treated with 8-MOP + 
UVA, it will still be referred to as leukapheresis (or leuk) throughout this document.   
 
Overnight culture of patient samples 
To mimic transimmunization, the peripheral blood mononuclear cells (PBMCs) were 
isolated from the ECP sample by centrifugation over a Ficoll-Hypaque gradient.  Half of 
the total lymphocytes isolated from the ECP sample buffy layer were washed 2x with 10 
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ml Hank’s balanced salt solution (HBSS, Gibco, Carlsbad, CA) + 1% 
Penicillin/Streptomycin (Pen/Strep, Gibco, Carlsbad, CA) and then resuspended in 
RPMI-1640 medium (Gibco, Carlsbad, CA), supplemented with 1% Pen/Strep and 15% 
pooled normal AB serum (Gemini Bio-Products, West Sacramento, CA).  Cells were 
plated in 6-well polystryene tissue culture plates (BD Falcon, Franklin Lakes, NJ) and 
were cultured at 37°C in 5% CO2 at a density of 5 x 106 cells/ml.  Following overnight 
culture (20 hours) cells were harvested using a cell scraper and were washed 1x with 10 
ml of RPMI-1640 + 1% Pen/Strep before undergoing enrichment for the monocyte 
population.  For all of the patient samples, I performed the sample preparation and set up 
the cell cultures.   
 
Normal control samples 
A 5 ml sample of untreated whole blood was obtained immediately prior to the 
leukapheresis procedure.  Peripheral blood leukocytes from healthy normal control 
donors were isolated by leukapheresis using the Baxter CS-3000 apparatus.  A portion of 
the leukapheresis was set aside for RNA isolation.  The majority of the leukapheresis was 
treated with a bench-top ECP apparatus consisting of a bag containing the leukapheresis 
sample, a bag with normal saline, a pump, plastic tubing, UVA light box containing a 
plastic plate, and plastic collection bag.  The plastic plate used in this apparatus is 
identical to the plate used in the Therakos machine.  This system was designed to mimic 
the photopheresis system used to treat patient samples, however it has the advantage of 
being an open system, thereby providing access to samples of treated cells at different 
time points.  This open bench-top apparatus therefore allows for more detailed 
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mechanistic studies.  Samples of leukocytes that had been treated with 8-MOP and were 
undergoing ECP were taken at the following time points: 1 hour UVA exposure, 2 hours 
UVA exposure, and 3 hours UVA exposure.  These samples were divided and half of the 
sample buffy layer was cultured overnight in RPMI-1640 medium + 1% Pen/Strep, 7.5% 
pooled normal AB serum and 7.5% autologous serum (total 15% serum), in plastic tissue 
culture plates at 37°C, 5% CO2.  The remaining leukocytes that had been subjected to the 
entire 3 hour period of UVA radiation were cultured overnight in a 1 liter platelet storage 
bag (PL-2410, Baxter), as is used for transimmunization.  This bag is made of a plastizer 
that does not diffuse but makes the bag pliable, strong enough to withstand centrifugation 
and gas diffusible.  The cells can be resuspended by manipulating the soft bag, limiting 
cell loss due to sticking.  After overnight culture in the bag, the PBMCs were isolated by 
centrifugation over a Ficoll-Hypaque gradient.  A portion of these transimmunization-
treated cells were taken for RNA isolation.  For all normal control samples, the sample 
acquisition, treatment with the bench-top ECP apparatus, and cell cultures were 
performed by Dr. Carole Berger with the assistance of Nianci Wang.    
 
Cell isolation and enrichment for monocyte population 
Peripheral blood mononuclear cells (PBMCs) were isolated from patient and normal 
control samples by centrifugation over a Ficoll-Hypaque gradient.  Cells were washed 2x 
with RPMI 1640 (Gibco, Gaithersburg, MD) containing 10% AB serum, 1% Pen/strep, 
and 2 mM EDTA.  Subsequently PBMCs underwent magnetic bead depletion of the non-
monocyte populations.    To achieve enrichment of the monocyte population, samples 
were either depleted of the CD4+ fraction or depleted of the CD4+, CD8+, and CD19+ 
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fractions for a more rigorous isolation of the monocyte population.  For patient samples 
that were depleted of the CD4+ fraction, the PBMCs were incubated with 20 µl MACS α-
human CD4 microbeads (Miltenyi Biotech, Auburn, CA) per 1 x 107 cells and then 
passed over a column in a magnetic field, according to the manufacturer’s instructions.  
For some of the patient and normal control samples, the CD4+, CD8+, and CD19+ cell 
fractions were removed from DCs by incubation with a mixture of CD4, CD8, and CD19 
antibody conjugated to magnetic beads (Miltenyi Biotech, Auburn, CA) using 20 µl per 1 
x 107 cells of each antibody followed by passage over a column in a magnetic field, 
according to the manufacturer’s instructions.   I performed the monocyte enrichment on 
all patient samples and Dr. Carole Berger performed the monocyte enrichment on normal 
control samples.   
 
RNA isolation and microarray hybridization 
Total RNA was isolated using RNeasy Mini Kit columns with on-column DNase I 
treatment as described by the manufacturer (Qiagen, Hilden, Germany).  RNA yield and 
purity were measured using the NanoDrop ND-1000 Spectrophotometer and the Agilent 
2100 Bioanalyzer.  An oligo- dT primer containing the promoter sequence of the 
bacteriophage T7 RNA polymerase was then used to synthesize double-stranded cDNA 
from 1 ug of total RNA by the One-Cycle cDNA Synthesis Kit (Affymetrix Inc., Santa 
Clara, CA).  The cDNA was subsequently cleaned up by the GeneChip Sample Cleanup 
Module (Affymetrix Inc.).  Next the cDNA was in vitro transcribed into biotin-labeled 
anti-sense mRNA (referred to as cRNA), using the oligo- dT primer and biotinylated 
ribonucleotides contained in the GeneChip IVT Labeling Kit (Affymetrix Inc.).  Clean-up 
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of the biotinylated cRNA was performed using the Sample Cleanup Module.  The 
biotinylated cRNA is then fragmented to a size of 35-200 bases by incubating at 94º C for 
35 minutes in fragmentation buffer (40 mM Tris-acetate, pH 8.1, 100 mM potassium 
acetate, 30 mM magnesium acetate).  The chemically fragmented biotinylated cRNAs are 
then added to hybridization buffer (100 mM MES, 1M [Na], 20 mM EDTA, 0.01% 
Tween 20, herring sperm DNA (0.1 mg/ml; Promega), fragmented cRNA (0.05μg/μl)).  
Acetylated BSA (0.5 mg/ml, Invitrogen) and four control bacterial and phage cRNA (1.5 
pM BioB, 5 pM Bio C, 25 pM BioD, and 100 pM Cre) samples were also included in the 
hybridization buffer to serve as internal controls for hybridization efficiency.  The 
hybridization buffer was placed on Affymetrix HG U133 Plus 2.0 human chips and the 
arrays were hybridized for 16 h at 45°C
 
in a rotisserie oven (GeneChip Hybridization 
Oven 640, Affymetrix Inc).  After hybridization, arrays were washed and stained with 
streptavidin-phycoerythrin, a fluorescent molecule that binds to biotin.  Because 
biotinylated cRNAs were hybridized to the arrays, the streptavidin-phycoerythrin binds 
the hybridized cRNA.  After the first staining with streptavidin-phycoerythrin, a standard 
signal amplification step was performed that employs anti-streptavidin antibody (goat) 
and biotinylated goat IgG antibody.  After this step the array is again incubated with 
streptavidin-phycoerythrin, providing an amplified level of fluorescence.  The washes 
and staining were carried out used the Affymetrix Fluidics Station 450 according to the 
following protocol: arrays were washed for 30 cycles with non-stringent Wash Buffer A 
(Affymetrix Inc), and then 18 cycles with stringent Wash Buffer B (Affymetrix Inc).  
Arrays were stained with Streptavidin-Phycoerythrin Solution (2X Stain Buffer, 50 
mg/mL BSA, 1 mg/mL streptavidin phycoerythrin) for 10 min at 25°C, 5 minutes at 
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35°C, then again for 10 min at 25°C. Arrays were then washed for 30 cycles with Wash 
Buffer A.  Next, arrays were incubated with the Anti-Streptavidin Antibody solution to 
amplify the signal.  The Antibody Solution (2X Stain Buffer, 50 mg/mL BSA, 10 mg/mL 
Goat anti-streptavidin, 0.5 mg/mL biotinylated Goat IgG) was incubated for 10 min at 
25°C, 5 minutes at 35°C, then again for 10 min at 25°C.  The arrays were then stained 
with the Streptavidin Phycoerythrin Solution for a second time for 10 min at 25°C, 5 
minutes at 35°C, then again for 10 min at 25°C.  Finally, a wash with 45 cycles of Wash 
Buffer A was performed.  The array was then scanned on an Affymetrix GeneChip 
Scanner 3000, a confocal scanner that measures the fluorescence intensity emitted by the 
labeled cRNA bound to the probe arrays. The amount of light emitted at 570 nm is 
proportional to the bound target at each location on the probe array.  I performed the 
RNA isolation on all samples, with the exception of several samples from normal control 
individuals that were isolated by Zimei Zhang.  The Affymetrix Microarray Facility at the 
Yale University W. M. Keck Foundation Biotechnology Resource Laboratory performed 
the measurements of RNA yield and purity, the synthesis, labeling, and hybridization of 
cRNA to the Affymetrix GeneChip, and the labeling and scanning of the GeneChip. 
 
Data Analysis 
Raw data without normalization generated from Affymetrix GeneChip® Operating Soft-
ware Version 1.2 (GCOS 1.2) (Affymetrix Inc.) were analyzed using GeneSpring 
software 7.2 (Agilent Technologies-Silicon Genetics, Redwood City, CA).  Data was 
normalized using Robust Multi-Array (RMA) normalization. Only those probe sets with a 
minimal fold change of 2.0 combined with an average signal intensity of 500 or higher in 
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either the leukapheresis or treated samples were included in the analysis.  Comparisons 
were made between leukapheresis samples and ECP-treated samples, and also between 
leukapheresis samples and TI-treated samples.  Differential gene expression was 
considered as a ≥ 2-fold change and P-value ≤0.05.  Dr. Aiping Lin, a biostatistician at 
the Keck Biotechnology Resource who specializes in microarray analysis, performed the 
normalization and analysis of the raw microarray data.  To identify pathways relevant to 
ECP and TI-induced DC, we used MetaCore Software (GeneGo Inc, St Joseph, MI), 
which is a curated database containing approximately 500 canonical signaling and 
metabolic pathways.  This pathway data was generated using a stringent method 
recommended by Dr. Aiping Lin.  Because the gene expression data from the 3 CTCL 
and 3 GVHD patients was extremely similar, Dr. Lin recommended we combine this data 
to look at gene expression changes as a result of TI across the patient groups.  This 
strengthened the statistical significance of our data, because the sample size was N=6, 
instead of N=3 when the patient groups were analyzed separately.  To analyze 
significantly involved pathways as a result of treatment, combined gene lists for ECP 
versus leukapheresis and TI versus leukapheresis consisting of all genes with a fold-
change of ≥ 2 and P-value ≤0.05 were up-loaded onto the MetaCore Software.  Using 
MetaCore algorithms, a list of the most significantly involved pathways was generated, 
including P-values representing the likelihood that a given pathway is affected by ECP or 






Quantitative real-time polymerase chain reaction: Validation of microarray data 
To validate alterations in gene expression on the microarray, changes in the expression of 
selected genes were confirmed in aliquots of the same RNA samples used for the 
microarray using quantitative real-time PCR.  First, RNA was reverse transcribed to 
cDNA using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA).  Each 20 μl reaction contained: 1 μg RNA, 2.0 μl 10X RT Buffer, 0.8 
μl dNTP Mix, 2.0 μl RT Random Primers, 1.0 μl MultiScribe Reverse Transcriptase, 1.0 
μl RNase inhibitor, and nuclease-free H2O to make a 20 μl reaction volume.  Reverse 
transcription was carried out in a 96-well thermocycler (MJ Research PTC-200) in the 
following conditions: 25°C for 10 min, 37°C for 120 min, 85°C for 5 sec.  For 
quantitative real-time PCR, each 25 μl reaction contained: 200 ng cDNA, 12.5 μl 
TaqMan Universal PCR MasterMix, 1.25 μl TaqMan probe, and nuclease-free H2O to 
make a 25 μl reaction.  All quantitative PCR reactions were performed as singleplex 
(using one probe per reaction) and in triplicate. TaqMan real-time PCR was used to 
detect transcripts of DC-LAMP, CCR7, Indoleamine, and CD14.  Primers and probes for 
each sequence were obtained as Inventoried Taqman Gene Expression Assays and are 
listed as Gene Symbol: Assay ID (Applied Biosystems, Foster City, CA: TaqMan FAM-
MGB probes: DC-LAMP: Hs00180880_m1, CCR7: Hs00171054_m1, Indoleamine: 
Hs00158032_m1, CD14: Hs00169122_g1).  HPRT1was used as reference gene.  
Quantitative PCR was performed using an Applied Biosystems 7500 Real-Time PCR 
system with the following temperature profile: 50 °C for 2 min, 95 °C for 10 min, 
followed by 40 cycles of denaturation at 95°C for 15 seconds and 60°C for 60 seconds.  
Quantification of transcripts was made by the comparative computed tomography 
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method.  I performed all of the quantitative real-time PCR for validation of the 
microarray data.   
 
Quantitative real-time polymerase chain reaction: Validation of target genes in patient 
and normal control samples 
For a select group of patients and for all normal controls, we compared gene expression 
changes after treatment to a baseline expression level in untreated, whole blood drawn 
directly from the patient.  Because the monocyte-enriched cell population we isolated 
from whole blood contained few cells, we had very small quantities of cDNA.  The 
Applied Biosystems TaqMan® PreAmp Master Mix Kit was used to increase the quantity 
of cDNA for gene expression studies in all samples.  Before running the preamplification 
reaction, the TaqMan Assays of interest (containing primers and probes) including 
endogenous control HPRT-1 were pooled together, as per the manufacturer’s instructions 
with all assays at a final concentration of 0.2X in 1X Tris–EDTA (TE) buffer.  Each 
preamplification reaction contained 25 μl TaqMan PreAmp MasterMix, 12.5 μl pooled 
assay mix, and up to 250 ng cDNA + nuclease free water to make 12.5 μl for a total 
reaction volume of 50 μl.  The preamplification reaction was performed in a 96-well 
thermocycler (MJ Research PTC-200) in the following conditions: 95°C for 10 min, and 
95°C for 15s followed by 60°C for 4 min for 14 cycles.  In order to perform TaqMan 
real-time PCR, the preamplified products were diluted 1:20 using TE buffer.  The gene 
expression reaction was performed in 25 μl reactions containing 12.5 μl Gene Expression 
Master Mix, 1.25 μl TaqMan Gene Expression Assay, 6.25 μl preamplified cDNA 
product, and 5 μl nuclease-free water.  All reactions were singleplex and were performed 
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in triplicate.  The following Inventoried TaqMan Gene Expression Assays (FAM-MGB 
probes, listed as Gene Symbol: Assay ID) were used: DC-LAMP: Hs00180880_m1, 
CD80: Hs00175478_m1, CD40: Hs00386848_m1, CD14: Hs00169122_g1, CD86: 
Hs00199349_m1, GPNMB: Hs00159620_m1.  HPRT1was used as reference gene.  
Quantitative PCR was performed using an Applied Biosystems 7500 Real-Time PCR 
system using the following thermal cycling conditions: 50°C for 2 min, 95°C for 10 min 
followed by 40 cycles of denaturation at 95°C for 15 seconds and 60°C for 60 seconds.  
Quantification of transcripts was made by the comparative computed tomography 
method.  I and Zimei Zhang performed the preamplification and quantitative real-time 





Transcriptional response induced by ECP and TI  
Samples from 3 CTCL and 3 GVHD patients undergoing ECP were depleted of CD4+ T 
cells and then hybridized to Affymetrix U133 plus 2.0 gene chips.  For each patient, an 
array measuring RNA transcript levels at the end of the leukapheresis phase of ECP 
(immediately before 8-MOP is added) was used as a baseline array, and fold-change in 
gene expression was determined as a change in RNA transcript from this baseline.  For 
all 6 patients, RNA transcript levels were then assessed after ECP treatment on Day 0 and 
after ECP + overnight incubation (TI).  After ECP treatment, the number of genes that 
were significantly differentially expressed (≥ 2 fold change, P ≤ 0.05) in the samples 
from 3 CTCL patients was 206 (202 up-regulated genes, 4 down-regulated genes).  The 
transcriptional response induced by TI was much greater than the response induced by 
ECP.  For the 3 CTCL patients, following TI there were 4553 genes significantly 
differentially expressed (2868 up-regulated genes, 1685 down-regulated genes).  For the 
3 GVHD patients there were 72 genes significantly up or down regulated (63 up-
regulated, 9 down-regulated) after ECP.  Post-TI treatment there were 3966 genes 
significantly differentially expressed (2191 up-regulated, 1775 down-regulated) in 
GVHD patients. 
 
Most up and down regulated genes 
The most differentially expressed genes in each group are listed in Tables 1-4.  Table 1 
lists the top 50 up-regulated genes in CTCL patients after TI.  Table 2 lists the top 50 up-
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regulated genes in GVHD patients after TI.  In comparing these lists, it is clear that many 
of the same genes are highly up-regulated after TI in both CTCL and GVHD patients.  In 























Function                                               
(Gene Ontology Biological Process)
Fold change 
(TI/Leuk) P-value
NM_002510 Glycoprotein nmb Negative regulation of cell proliferation 2393.02 6.9E-04
BG166705 chemokine (C-X-C motif) ligand 5 Chemotaxis 747.97 2.6E-04
L27624 Tissue factor pathway inhibitor 2 Blood coagulation 482.34 1.2E-03
N30257 Solute carrier family 16, member 10 Transport 270.57 5.1E-04
NM 006843 Serine dehydratase gluconeogenesis 265.44 3.3E-02
NM_014331 Solute carrier family 7, member 11 Protein complex assembly 258.16 7.3E-05
NM 002030 Formyl peptide receptor-like 2 Chemotaxis 251.45 1.1E-03
AB000889 Phosphatidic acid phosphatase type 2B Lipid metabolism 201.10 1.1E-04
AA977975 Vitelline membrane outer layer 1 homolog --- 198.83 1.9E-04
NM 002993 chemokine (C-X-C motif) ligand 6 Inflammatory response 197.41 1.6E-04
NM_014479 ADAM-like, decysin 1 Integrin-mediated signaling pathway 190.32 1.1E-02
BG170541 Met proto-oncogene (hepatocyte growth factor receptor) Protein amino acid phosphorylation 180.15 4.1E-06
M34455 Indoleamine-pyrrole 2,3 dioxygenase Tryptophan catabolism 174.70 5.2E-04
BG236136 Unknown (Similar to Immune-responsive protein 1 in mouse) --- 147.49 2.8E-03
NM 004591 Chemokine (C-C motif) ligand 20 Inflammatory response 144.76 1.9E-02
M83248 Osteopontin Cell adhesion 139.27 3.3E-04
AF003934 Growth differentiation factor 15 TGF beta receptor signaling pathway 128.77 1.2E-03
NM 003020 Secretogranin V (7B2 protein) Protein folding 117.07 1.9E-02
AI608902 Unknown (transcibed locus) --- 107.35 3.5E-05
BF513121 Integrin, beta 8 Cell adhesion 100.45 2.7E-05
U38321 matrix metallopeptidase 19 Peptidoglycan metabolism 87.39 2.3E-03
AB051513 Zinc finger CCCH-type containing 12C --- 86.35 5.2E-04
NM 003122 Serine peptidase inhibitor, Kazal type 1 --- 84.82 1.4E-03
M86849 Connexin 26 Cell-cell signaling 79.29 4.0E-04
NM 004403 Deafness, autosomal dominant 5 Sensory perception of sound 77.58 5.9E-04
AL577322 Syndecan 2 --- 66.12 1.5E-03
D55696 Legumain Proteolysis 63.56 1.7E-02
AK026883 G protein-coupled receptor 157 Signal transduction 60.20 3.4E-05
NM 001442 Fatty acid binding protein 4, adipocyte Transport 60.05 1.5E-02
NM 014398 Lysosomal-associated membrane protein --- 59.83 5.1E-03
AL389942 Unknown (hypothetical protein LOC285628) --- 58.24 1.8E-03
AI659800 Chromosome 13 open reading frame 31 --- 56.38 4.5E-04
AJ276888 Transformed 3T3 cell p53 binding protein Regulation of cell cycle 51.61 3.5E-04
NM 004110 Ferredoxin reductase Electron transport 49.69 3.8E-04
NM_000064 Complement component 3 Inflammatory response 49.08 3.6E-04
BF511231 Tissue factor pathway inhibitor 2 Blood coagulation 44.88 7.9E-05
BE566894 Leukotriene B4 12- Leukotriene metabolism 43.12 3.1E-05
NM 006850 Interleukin 24 Apoptosis 42.52 5.9E-04
BC042665 CD80 molecule Immune response 41.89 7.8E-04
AB042557 Phosphodiesterase 4D interacting protein Protein biosynthesis 40.93 3.3E-03
CTCL 50 most up-regulated genes
Table 1.  50 most up-regulated genes after TI in CTCL patients                       
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline. RNA 
was isolated from the CD4- cell fraction from 3 CTCL patients following leukapheresis and after 
ECP + overnight incubation (TI).  All samples were processed identically and array data was 




























Function                                               
(Gene Ontology Biological Process)
Fold change 
(TI/Leuk) P-value
AI343467 CDNA FLJ11041 fis, clone PLACE1004405 --- 40.20 5.5E-03
NM 000600 Interleukin 6 Immune response 40.09 4.9E-03
NM_013231 Fibronectin leucine rich transmembrane protein 2 Cell adhesion 39.84 1.4E-03
NM 004994 Matrix metallopeptidase 9 Peptidoglycan metabolism 38.02 1.4E-03
L03203 Peripheral myelin protein 22 Synaptic transmission 38.00 1.5E-04
AK024680 Neuropilin 2 Cell adhesion 37.90 1.9E-05
AU149305 Matrix metallopeptidase 14 Peptidoglycan metabolism 35.88 4.3E-04
AB033025 KIAA1199 Sensory perception of sound 34.76 2.6E-06
AI422414 Carboxypeptidase M Proteolysis 33.34 1.0E-04
AF228422 Chromosome 15 open reading frame 48 --- 32.91 1.2E-02
CTCL 50 most up-regulated genes continued
Table 1 cont.  50 most up-regulated genes after TI in CTCL patients continued             
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline. RNA was 
isolated from the CD4- cell fraction from 3 CTCL patients following leukapheresis and after ECP + 
overnight incubation (TI).  All samples were processed identically and array data was analyzed using 




























Function                                               
(Gene Ontology Biological Process)
Fold change 
(TI/Leuk) P-value
NM_002510 Glycoprotein nmb Negative regulation of cell proliferation 1527.98 4.5E-04
M83248 Osteopontin Cell adhesion 677.58 1.4E-03
BG166705 Chemokine (C-X-C motif) ligand 5 Chemotaxis 661.29 1.5E-03
AI984980 Chemokine (C-C motif) ligand 8 Inflammatory response 436.37 1.9E-02
AA488687 Solute carrier family 7, member 11 Protein complex assembly 399.79 2.3E-04
NM_002993 Chemokine (C-X-C motif) ligand 6 Inflammatory response 257.84 1.8E-02
NM_006843 Serine dehydratase gluconeogenesis 255.07 4.0E-02
BF513121 Integrin, beta 8 Cell adhesion 245.91 2.3E-03
BG170541 Met proto-oncogene (hepatocyte growth factor receptor) Protein amino acid phosphorylation 221.23 1.0E-03
N30257 Solute carrier family 16, member 10 Transport 218.39 1.2E-04
AI343467 CDNA FLJ11041 fis, clone PLACE1004405 --- 197.53 4.1E-02
AB000889 Phosphatidic acid phosphatase type 2B Lipid metabolism 184.59 2.2E-05
NM_004591 Chemokine (C-C motif) ligand 20 Inflammatory response 182.82 1.4E-02
U38321 Matrix metallopeptidase 19 Peptidoglycan metabolism 175.69 1.3E-04
NM_002030 Formyl peptide receptor-like 2 Chemotaxis 158.98 2.6E-03
BG236136 Unknown (Similar to Immune-responsive protein 1 in mouse) --- 153.14 4.6E-05
M13436 Inhibin, beta A Induction of apoptosis 144.90 2.9E-02
NM_003122 Serine peptidase inhibitor, Kazal type 1 --- 127.75 8.4E-06
NM_004403 Deafness, autosomal dominant 5 Sensory perception of sound 124.38 4.4E-04
NM_014398 Lysosomal-associated membrane protein --- 109.17 4.8E-04
AA977975 Vitelline membrane outer layer 1 homolog --- 108.49 8.4E-04
AF003934 Growth differentiation factor 15 TGF beta receptor signaling pathway 103.26 9.2E-04
AB051513 Zinc finger CCCH-type containing 12C --- 91.82 1.0E-04
AF228422 Chromosome 15 open reading frame 48 --- 87.67 6.6E-03
AI608902 Unknown (transcibed locus) --- 70.22 3.6E-03
M86849 Connexin 26 Cell-cell signaling 68.52 1.3E-03
BF511231 Tissue factor pathway inhibitor Blood coagulation 68.50 1.4E-03
AA031832 Hypothetical gene supported by BC008048 --- 67.30 1.0E-04
NM_014479 ADAM-like, decysin 1 Integrin-mediated signaling pathway 64.97 5.3E-04
NM_001511 chemokine (C-X-C motif) ligand 1 Chemotaxis 61.75 4.8E-03
M34455 Indoleamine-pyrrole 2,3 dioxygenase Tryptophan catabolism 55.52 2.8E-03
AK026883 G protein-coupled receptor 157 Signal transduction 53.91 2.4E-03
AL389942 Unknown (hypothetical protein LOC285628) --- 51.66 9.4E-03
NM_002658 Plasminogen activator, urokinase Proteolysis 46.26 2.8E-03
NM_005114 Heparan sulfate 3-O-sulfotransferase 1 --- 45.87 6.3E-03
NM_007115 tumor necrosis factor, alpha-induced protein 6 Inflammatory response 45.41 8.2E-03
AU149305 Matrix metallopeptidase 14 Peptidoglycan metabolism 44.18 4.1E-03
GVHD 50 most up-regulated genes
Table 2.  50 most up-regulated genes after TI in GVHD patients                       
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline. RNA 
was isolated from the CD4- cell fraction from 3 GVHD patients following leukapheresis and after 
ECP + overnight incubation (TI).  All samples were processed identically and array data was 














Tables 3 and 4 list the 50 most down-regulated genes in CTCL and GVHD patients, 
respectively.  Again, we see that many (66%) of the most down-regulated genes are the 
same on both lists.  Looking at the gene ontology biological process in each of these 
groups, it appears that there are many genes involved in the inflammatory immune 
response, cell adhesion, and regulation of apoptosis that are highly up-regulated, while 









Function                                               
(Gene Ontology Biological Process)
Fold change 
(TI/Leuk) P-value
BC035749 Chromosome 13 open reading frame 31 --- 43.64 4.9E-05
AI859620 Interleukin 4 induced 1 Electron transport 42.13 3.8E-03
L03203 Peripheral myelin protein 22 Synaptic transmission 41.24 3.0E-02
BC042665 CD80 molecule Immune response 40.00 2.2E-04
AL577322 Syndecan 2 --- 38.62 4.8E-03
D55696 Legumain Proteolysis 37.49 2.0E-03
NM_013410 Adenylate kinase 3-like 1 Nucleic acid metabolism 36.30 4.9E-03
NM_002090 Chemokine (C-X-C motif) ligand 3 Chemotaxis 35.89 1.2E-03
AK024680 Neuropilin 2 Cell adhesion 35.89 8.1E-04
NM_022359 Phosphodiesterase 4D interacting protein Protein biosynthesis 34.45 3.4E-04
AI827972 Methyltransferase like 7B --- 33.12 2.4E-02
BC016631 Chromosome 7 open reading frame 10 Metabolism 32.47 1.5E-02
AF035776 Oxidised low density lipoprotein receptor 1 Inflammatory response 32.26 1.2E-02
GVHD 50 most up-regulated genes continued
Table 2 cont.  50 most up-regulated genes after TI in GVHD patients continued             
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline. RNA 
was isolated from the CD4- cell fraction from 3 GVHD patients following leukapheresis and after 
ECP + overnight incubation (TI).  All samples were processed identically and array data was 




























Function                                                  
(Gene Ontology Biological Process)
Fold change 
(TI/Leuk) P-value
NM_000110 Dihydropyrimidine dehydrogenase De novo pyrimidine base biosynthesis -113.82 1.1E-04
NM_000129 Coagulation factor XIII, A1 polypeptide Blood coagulation / -76.66 6.1E-04
AI052659 Complement component (3b/4b) receptor 1 Complement activation -67.83 6.9E-04
AA650281 STEAP family member 4 Electron transport -66.16 1.5E-03
NM_018460 Rho GTPase activating protein 15 Regulation of cell shape -61.97 3.5E-04
BF032500 Chromosome 20 open reading frame 133 --- -61.39 2.7E-04
NM_007309 Diaphanous homolog 2 (Drosophila) Cytokinesis -55.75 8.3E-06
NM_013378 Pre-B lymphocyte gene 3 --- -53.46 7.4E-04
NM_017935 B-cell scaffold protein with ankyrin repeats 1 --- -47.90 1.1E-03
U90339 Adenosine kinase Purine ribonucleoside salvage -47.06 3.5E-04
AA677057 Fc receptor-like 1 --- -46.29 2.6E-03
AI654161 TBC1 domain family, member 5 --- -46.03 7.6E-04
NM_013959 Neuregulin 1 Nervous system development -45.41 3.7E-04
AA029441 Calcium/calmodulin-dependent protein kinase (CaM kinase) II delta Regulation of cell growth -45.35 1.7E-03
AA528080 Hypothetical protein LOC283070 --- -42.75 1.1E-04
BC003574 T-cell leukemia/lymphoma 1A Development -41.93 4.4E-03
NM_002738 Protein kinase C, beta 1 Protein amino acid phosphorylation -41.00 1.9E-03
AL833097 MRNA; cDNA DKFZp313E1515 --- -40.61 1.7E-03
AI733027 Retinol binding protein 7, cellular Transport -39.65 7.9E-05
AW003297 Ral GEF with PH domain and SH3 binding motif 2 GTPase mediated signal transduction -35.68 1.3E-03
NM 022445 Thiamin pyrophosphokinase 1 Thiamin metabolism -33.13 1.7E-03
AI927701 Chromosome 5 open reading frame 21 --- -33.09 6.8E-04
AW085505 AF4/FMR2 family, member 3 Regulation of transcription -32.60 5.0E-03
BC036784 RasGEF domain family, member 1B GTPase mediated signal transduction -32.55 3.0E-03
AW130600 MRNA; cDNA DKFZp564O0862 --- -31.10 2.2E-03
NM_006567 Phenylalanine-tRNA synthetase 2 Protein biosynthesis -28.82 1.0E-04
AB051486 Exocyst complex component 4 Vesicle docking during exocytosis -28.76 5.6E-05
AW080339 Brain and reproductive organ-expressed (TNFRSF1A modulator) Response to DNA damage stimulus -28.40 3.8E-04
NM_017784 Oxysterol binding protein-like 10 Lipid transport -28.03 2.2E-04
NM_002003 Ficolin (collagen/fibrinogen domain containing) 1 Phosphate transport -27.29 4.1E-04
AL049593 Phospholipase C, beta 1 Regulation of cell cycle -26.92 2.8E-04
NM 001500 GDP-mannose 4,6-dehydratase Leukocyte adhesion -26.88 2.4E-03
AI052003 Vacuolar protein sorting 13B --- -25.74 2.3E-04
NM_007053 CD160 molecule Cellular defense response -24.93 7.0E-04
N39230 Transcribed locus --- -24.88 3.9E-04
BF221852 LIM domain containing preferred translocation partner in lipoma Cell adhesion -24.70 1.4E-04
CTCL 50 most down-regulated genes
Table 3.  50 most down-regulated genes after TI in CTCL patients                       
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline. RNA 
was isolated from the CD4- cell fraction from 3 CTCL patients following leukapheresis and after 
ECP + overnight incubation (TI).  All samples were processed identically and array data was 




























Function                                                  
(Gene Ontology Biological Process)
Fold change 
(TI/Leuk) P-value
AI244661 Membrane protein, palmitoylated 7 --- -24.47 7.0E-04
AA020010 Kruppel-like factor 12 Regulation of transcription -23.87 7.1E-04
AF094700 Fas (TNFRSF6) associated factor 1 Apoptosis -23.23 9.6E-05
NM_024829 Hypothetical protein FLJ22662 --- -23.14 2.3E-03
BF112093 CDNA FLJ30652 fis --- -22.39 6.0E-04
W60686 LPS-responsive vesicle trafficking, beach and anchor containing Regulation of DNA replication -22.26 3.9E-04
BC001886 Ribonucleotide reductase M2 polypeptide DNA replication -21.11 2.0E-03
AL137430 --- --- -20.08 7.8E-05
BC001252 Dymeclin --- -19.80 1.7E-03
R62453 RAB37, member RAS oncogene family Regulation of transcription -19.79 3.3E-04
BC005912 Receptor for Fc fragment of IgE, high affinity I, alpha polypeptide Immune response -19.26 1.3E-03
AW205790 Sec1 family domain containing 2 Vesicle docking during exocytosis -18.94 5.8E-05
NM_002758 Mitogen-activated protein kinase kinase 6 DNA damage induced protein phosphorylation -18.77 4.8E-05
NM_024820 DENN/MADD domain containing 1A --- -18.42 1.3E-04
CTCL 50 most down-regulated genes continued
Table 3 cont.  50 most down-regulated genes after TI in CTCL patients continued             
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline. RNA 
was isolated from the CD4- cell fraction from 3 CTCL patients following leukapheresis and after 
ECP + overnight incubation (TI).  All samples were processed identically and array data was 




























Function                                                 
(Gene Ontology Biological Process)
Fold change 
(TI/Leuk) P-value
NM_000110 Dihydropyrimidine dehydrogenase De novo pyrimidine base biosynthesis -455.61 6.6E-10
NM_018460 Rho GTPase activating protein 15 Regulation of cell shape -115.21 4.7E-05
NM_007309 Diaphanous homolog 2 (Drosophila) Cytokinesis -76.05 6.8E-08
NM_022445 Thiamin pyrophosphokinase 1 Thiamin metabolism -71.70 5.1E-05
AI300084 TBC1 domain family, member 5 --- -66.88 5.0E-06
AI052659 Complement component (3b/4b) receptor 1 Complement activation -63.33 1.5E-05
U90339 Adenosine kinase Purine ribonucleoside salvage -58.81 4.7E-03
AL049593 Phospholipase C, beta 1 Regulation of cell cycle -55.33 3.9E-03
NM_006567 Phenylalanine-tRNA synthetase 2 Protein biosynthesis -54.17 3.9E-06
BC001886 Ribonucleotide reductase M2 polypeptide DNA replication -53.32 2.4E-02
AI052003 Vacuolar protein sorting 13B --- -50.81 7.1E-05
AA020010 Kruppel-like factor 12 Regulation of transcription -46.84 1.2E-03
AL833097 MRNA; cDNA DKFZp313E1515 --- -46.07 8.4E-04
AF094700 Fas (TNFRSF6) associated factor 1 Apoptosis -45.67 4.1E-05
AI927701 Chromosome 5 open reading frame 21 --- -42.43 1.7E-04
N66570 Utrophin (homologous to dystrophin) Muscle contraction -42.28 3.5E-04
NM_007124 --- --- -40.30 2.5E-04
AI961231 Thymus high mobility group box protein TOX Regulation of transcription -39.07 8.3E-04
NM_000129 Coagulation factor XIII, A1 polypeptide Blood coagulation -38.39 1.9E-03
AI659561 LPS-responsive vesicle trafficking, beach and anchor containing Regulation of DNA replication -36.94 9.8E-04
NM_013959 Neuregulin 1 Nervous system development -36.92 3.9E-02
AA045175 Membrane-spanning 4-domains, subfamily A, member 6A Signal transduction -36.58 1.1E-02
NM 002738 Protein kinase C, beta 1 Protein amino acid phosphorylation -35.76 3.4E-05
AI244661 Membrane protein, palmitoylated 7 --- -35.54 2.9E-04
NM_018318 Coiled-coil domain containing 91 Protein transport -35.30 2.2E-05
NM_003726 Src family associated phosphoprotein 1 Immune response -34.05 1.8E-03
AI420817 CDNA FLJ45742 fis --- -32.50 6.0E-04
NM_001500 GDP-mannose 4,6-dehydratase Leukocyte adhesion -32.47 1.4E-04
NM_007053 CD160 molecule Cellular defense response -32.04 9.9E-03
N63244 Tubulin, beta 1 Microtubule-based movement -31.27 4.0E-03
NM_013233 Serine threonine kinase 39 Protein amino acid phosphorylation -30.46 9.1E-04
AW276572 SET binding factor 2 Signal transduction -30.08 1.3E-04
AI498747 V-set and transmembrane domain containing 1 --- -28.78 4.3E-03
AA029441 Calcium/calmodulin-dependent protein kinase (CaM kinase) II delta Regulation of cell growth -28.63 8.1E-04
GVHD 50 most down-regulated genes
Table 4.  50 most down-regulated genes after TI in GVHD patients                       
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline. RNA 
was isolated from the CD4- cell fraction from 3 GVHD patients following leukapheresis and after 
ECP + overnight incubation (TI).  All samples were processed identically and array data was analyzed 
















TI induces a similar gene expression profile in patients with CTCL and GVHD 
Dr. Aiping Lin, a biostatistician specializing in microarray analysis, analyzed the entire 
data set containing all of the genes that were differentially expressed after TI (both up 
and down regulated) in CTCL and GVHD patients.  Dr. Lin first performed a cluster 
analysis of our entire data set.  Cluster analysis is a technique for viewing distinct 
patterns of gene expression within a dataset (33).  Using the hierarchical clustering 
technique, which assigns a similarity score to all gene pairs and calculates the Pearson’s 
correlation coefficient for the pair, Dr. Lin was able to view the data as a gene list 
organized into a dendrogram, or tree-diagram.  Per Dr. Lin, this analysis showed that our 
expression data clustered based on TI treatment and not disease process (personal 
Accession No. 
(Genbank) Description
Function                                                 
(Gene Ontology Biological Process)
Fold change 
(TI/Leuk) P-value
AI569476 Mastermind-like 3 (Drosophila) Regulation of transcription -28.00 1.5E-03
BG200452 B-cell scaffold protein with ankyrin repeats 1 --- -27.47 1.3E-02
AB051486 Exocyst complex component 4 Vesicle docking during exocytosis -27.28 4.3E-06
NM_002108 Histidine ammonia-lyase Histidine catabolism -26.96 2.3E-03
NM_024820 DENN/MADD domain containing 1A --- -26.85 7.8E-05
BF112093 CDNA FLJ30652 fis --- -26.49 9.4E-05
BC001252 Dymeclin --- -26.49 1.2E-05
AW130600 MRNA; cDNA DKFZp564O0862 --- -26.37 4.5E-03
U20350 chemokine (C-X3-C motif) receptor 1 Chemotaxis -26.33 9.5E-03
R62453 RAB37, member RAS oncogene family Regulation of transcription -26.27 8.5E-04
BF739885 Hypothetical protein LOC284262 --- -26.24 9.5E-04
X82240 T-cell leukemia/lymphoma 1A Development -26.01 1.5E-02
NM_022746 MOCO sulphurase C-terminal domain containing 1 --- -25.59 2.1E-03
BE222668 solute carrier family 9, member 9 Ion transport -25.47 3.3E-04
NM_031311 Carboxypeptidase, vitellogenic-like Proteolysis -25.13 2.7E-03
AA528080 Hypothetical protein LOC283070 --- -24.24 6.2E-04
GVHD 50 most down-regulated genes continued
Table 4 cont.  50 most down-regulated genes after TI in GVHD patients continued             
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline. RNA 
was isolated from the CD4- cell fraction from 3 GVHD patients following leukapheresis and after 
ECP + overnight incubation (TI).  All samples were processed identically and array data was 
analyzed using GeneSpring software to identify differentially expressed genes, P-values are listed.
32 
 
communication, Dr. Aiping Lin, data not shown).  Because of this result, Dr. Lin created 
a gene list divided into 3 sections: 1) genes similarly changed after TI in both CTCL and 
GVHD patients, 2) genes that were only up or down regulated in CTCL patients, and 3) 
genes that were only up or down regulated in GVHD patients.  Analysis of this gene list 
showed that of the 4650 total genes that were significantly up or down regulated after TI, 
2798 (60%) were changed in a similar manner (same direction of regulation, similar fold 
change in gene expression) in both CTCL and GVHD patients.  1124 (24%) of up or 
down regulated genes were unique to CTCL patients and 728 (16%) were unique to 













 Because the majority of changes in gene expression were similar between the two patient 
































Figure 1:  CTCL and GVHD patients differentially express more genes in common after TI 
than genes uniquely expressed by one patient group.
Number of genes significantly differentially expressed (greater than or equal to 2 fold change, P 
less than or equal to 0.05) after TI in common between 3 CTCL patients and 3 GVHD patients 
was 2798 (60%).  There were 1124 genes significantly up or down regulated only in CTCL 
patients (24%) and 728 genes up or down regulated only in GVHD patients (16%) following TI.  




patients.  Therefore, for our main statistical and pathway analysis, we used this combined 
data set. 
 
TI induces a gene expression profile consistent with mature DC 
TI caused significant up-regulation of genes associated with DC maturation (Table 5).  
The fold changes listed in Tables 5-9 represent combined data (CTCL and GVHD), and 
are listed as fold change after TI as compared to a baseline gene expression level in the 
leukapheresis (Leuk) sample, followed by the P value indicating the significance of the 
change in gene expression.  Up-regulation of DC-LAMP (74.05 fold, P = 8.6E-07), a 
novel lysosome-associated membrane glycoprotein and marker specific for mature DC 
that is up-regulated during DC activation and differentiation (34) was observed after TI.  
CD80, a DC costimulatory signal for T cell activation, proliferation and cytokine 
production (35) that is expressed by DC (36)was up-regulated 40.98 fold, P=1.3E-08 
after TI.  CD86, another co-stimulatory molecule important for T cell activation (35), was 
found to have no change in gene expression after TI when using this data set from 
combined CTCL and GVHD patients.  Up-regulation of CD40, which is expressed on 
mature DC and plays a role in DC survival and cytokine secretion (37) was up-regulated 
2.33 fold, P=3.5E-03 after TI.  CCR7, a chemokine receptor that drives migration to 
lymphoid organs (38) has been shown to be up-regulated in LPS-stimulated mature DC 
(39) and was up-regulated after TI 2.53 fold, P = 2.6E-02.  Decysin, a disintegrin/ 
metalloprotease similar to bacterial proteinase which is up-regulated in LPS matured DC 
(40) was up-regulated after TI 116.74 fold, P=4.0E-06.  In addition, there was massive 
up-regulation (1904.31 fold, P=2.3E-08) of glycoprotein GPNMB, a gene recently 
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discovered to be up-regulated in mature DC (41).  The mouse homolog of GPNMB is 
also named dendritic cell-associated heparin sulfate proteoglycan-dependent integrin 
ligand (DC-HIL) and plays an important role in DC adhesion (42).  Consistent with DC 
maturation, monocyte-associated genes including CD33, a sialoadhesin adhesion 
molecule expressed on monocytes (43) that is down-regulated in mature DC (30), was 
down-regulated after TI -2.54 fold, P=4.3E-05.  CD36, a scavenger receptor (44) down-
regulated during the transition from immature DC to mature DC (30), was down-
regulated -4.17 fold, P=5.7E-03 after TI.  Finally, the receptor for IgG Fc fragment Ia (or 
CD64), which is involved in capture of antibody-opsonized antigen (45) was down-
regulated -7.01 fold, P=3.7E-04 after TI.  CD64 expression on DC is known to be lower 













Accession no. Description Function
(Genbank) TI/Leuk P-value
DC maturity genes
NM_014398 DC-LAMP Lysosomal protein involved in antigen processing 74.05 8.6E-07
BC042665 CD80 Co-stimulatory molecule 40.98 1.3E-08
NM_006889 CD86 Co-stimulatory molecule No change -
NM_001250 CD40 Involved in CD survival, cytokine secretion, and tumoricidal activity 2.33 3.5E-03
NM_001838 CCR7 Involved in migration, chemotaxis 2.53 2.6E-02
NM_014479 Decysin Expressed in LPS matured DC 116.74 4.0E-06
NM_002510 Glycoprotein NMB (GPNMB) Up-regulated in mature DC, transmembrane glycoprotein 1904.31 2.3E-08
Monocyte genes
NM_001772 CD33 Cell surface protein expressed on circulating monocytes -2.54 4.3E-05
M98399 CD36 Impairs DC maturation, receptor for apoptotic cells -4.17 5.7E-03
X14355 Receptor for IgG Fc fragment Ia Down-regulated in early stages of DC maturation -7.01 3.7E-04
Fold change after TI
CTCL + GVHD
Table 5. Up-regulation of specific DC markers and down regulation of monocyte markers after 
TI                                                              
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline.  RNA 
was isolated from the CD4- cell fraction from 3 CTCL patients and 3 GVHD patients following 
leukapheresis and after ECP + overnight incubation (TI).  All samples were processed identically and 
array data from 6 patients was analyzed using GeneSpring software to identify differentially 
expressed genes.  Because of the similar patterns in gene expression we were able to combine the 
CTCL + GVHD data sets. The fold changes in this table represent combined data from all 6 patients.  
P-values are listed.  
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TI induces increased expression of inflammatory cytokines and chemokines 
Among the TI-induced genes were those relevant to inflammatory immune responses, 
including several genes encoding inflammatory cytokines and chemokines (Table 6).  
Interleukin 6, a pro-inflammatory cytokine that is up-regulated in infection as well as in 
autoimmune diseases such are rheumatoid arthritis and Crohn’s disease (47), was up-
regulated after TI (49.36 fold, P=1.7E-03).  Interferon gamma, a pro-inflammatory 
cytokine that enhances DC maturation (48) was not changed in this combined CTCL and 
GVHD data set.  Interleukin 1-alpha, a potent inflammatory mediator (49), was up-
regulated 69.84 fold after TI, P=4.4E-03.  A closely related inflammatory cytokine, 
Interleukin 1-beta (49), was up-regulated 3.01 fold after TI, although the P-value did not 
reach significance.  Chemokines and their receptors play an important role in DC 
function (50) and several inflammatory chemokines were up-regulated after TI, such as 
CCL22 (danger signal, 18.05 fold, P=1.4E-08), CXCL5 (produced in response to 
stimulation with IL1-beta or TNF alpha, 708.25 fold, P=6.4E-08), CXCL6 (224.88 fold, 
P=8.1E-06), and CCL20 (156.38 fold, P=1.2E-04).  The chemokine receptor CCR5, 
which is involved in DC migration, was also induced by TI (6.51 fold, P=6.5E-04) (50).  
TI induced expression of receptors for inflammatory cytokines as well:  IL1R1, which 
leads to NFκB activation (23), was up-regulated 20.12 fold, P=1.4E-05, and IL7R, a 























TI induced changes in genes involved in antigen presentation 
Table 7 lists the expression of genes involved in antigen presentation on MHC class I, 
such as the MHC class I mRNA fragment 3.8-1 was up-regulated after TI (2.01 fold, 
P=9.7E-04), as well as expression of MHC class I-related gene, which interacts with 
MHC class I molecules (4.88 fold, P=1.4E-06) (52).  However, expression of MHC class 
II genes was down-regulated after TI: MHC class II DO beta (-6.20 fold, P=9.6E-03), 
MHC class II DP alpha 1 (-6.18 fold, P=6.7E-03), MHC class II DR beta 1 (-5.51 fold, 
Accession no. Description Function
(Genbank)
Inflammatory cytokines and 
chemokines TI/Leuk P-value
NM_000600 Interleukin 6 Up-regulated during bacterial and viral infections 49.36 1.7E-03
M29383 Interferon gamma Inflammatory cytokine No change -
M15329 Interleukin 1-alpha Potent inflammatory mediator 69.84 4.4E-03
NM_000576 Interleukin 1-beta Enhances DC maturation 3.01 1.3E-01
NM_002990 CC chemokine ligand 22 (CCL22) Danger signal 18.05 1.4E-08
BG166705 CXC chemokine ligand 5 (CXCL5)
Inflammatory cytokine, produced in response 
to IL1 or TNFalpha 708.25 6.4E-08
NM_002993 CXC chemokine ligand 6 (CXCL6) Inflammatory cytokine 224.88 8.1E-06
NM_004591 CC chemokine ligand 20 (CCL20) Inflammatory cytokine 156.38 1.2E-04
Inflammatory cytokine and 
chemokine receptors
NM_000877 Interleukin 1 receptor, type 1 (IL1R1) Leads to NFkB activation 20.12 1.4E-05
NM_002185 Interleukin 7 receptor Mediates lymphopoiesis 4.13 1.7E-03
NM_000579 CC chemokine receptor 5 (CCR5) Involved in DC migration 6.51 6.5E-04
Fold change after TI
CTCL + GVHD
Table 6. Up-regulation of Inflammatory cytokines and chemokines after TI                         
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline.  
RNA was isolated from the CD4- cell fraction from 3 CTCL patients and 3 GVHD patients 
following leukapheresis and after ECP + overnight incubation (TI).  All samples were processed 
identically and array data from 6 patients was analyzed using GeneSpring software to identify 
differentially expressed genes.  Because of the similar patterns in gene expression we were able to 
combine the CTCL + GVHD data sets. The fold changes in this table represent combined data 
from all 6 patients.  P-values are listed.
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P=1.3E-02), MHC class II DMB (-4.77 fold, P=1.5E-04), MHC class II DO alpha (-4.08 
fold, P=4.1E-02), MHC class II DP beta 1 (-3.38 fold, P=5.1E-03), MHC class II DQ 
beta 1 (-3.33 fold, P= 3.5E-02), and MHC class II DM alpha (-3.04 fold, P=7.7E-04).  
Also, the MHC class II transactivator, which controls expression of MHC class II genes, 
was down-regulated after TI (-3.39, P=2.6E-03).  In the field of DC biology, it is well 
established that the expression of MHC class II related genes is decreased in mature DC, 
and the up-regulation of MHC class II protein at the cell surface is due to major changes 
in the intracellular transport of MHC class II molecules, so the down-regulation of these 















Table 7. Differential expression of genes involved in antigen presentation                                           
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline.  
RNA was isolated from the CD4- cell fraction from 3 CTCL patients and 3 GVHD patients 
following leukapheresis and after ECP + overnight incubation (TI).  All samples were processed 
identically and array data from 6 patients was analyzed using GeneSpring software to identify 
differentially expressed genes.  Because of the similar patterns in gene expression we were able to 
combine the CTCL + GVHD data sets. The fold changes in this table represent combined data 
from all 6 patients.  P-values are listed.
Accession no. Description Function
(Genbank)
Antigen presentation TI/Leuk P-value
AF031469 Major histocompatibility complex, class I-related (MR1) Interacts with MHC Class I molecules 4.88 1.4E-06
AI346483 MHC class I mRNA fragment 3.8-1 Involved in MHC Class I antigen presentation 2.01 9.7E-04
NM_002120 Major histocompatibility complex, class II, DO beta (HLA-DOB)
Involved in MHC Class II antigen 
presentation -6.20 9.6E-03
AI128225 Major histocompatibility complex, class II, DP alpha 1 (HLA-DPA1)
Involved in MHC Class II antigen 
presentation -6.18 6.7E-03
AA807056 Major histocompatibility complex, class II, DR beta 1 (HLA-DRB1)
Involved in MHC Class II antigen 
presentation -5.51 1.3E-02
NM_002118 Major histocompatibility complex, class II, DM beta (HLA-DMB)
Involved in MHC Class II antigen 
presentation -4.77 1.5E-04
AL581873 Major histocompatibility complex, class II, DO alpha (HLA-DOA)
Involved in MHC Class II antigen 
presentation -4.08 4.1E-02
NM_002121 Major histocompatibility complex, class II, DP beta 1 (HLA-DPB1)
Involved in MHC Class II antigen 
presentation -3.38 5.1E-03
M32577 Major histocompatibility complex, class II, DQ beta 1 (HLA-DQB1)
Involved in MHC Class II antigen 
presentation -3.33 3.5E-02
X76775 Major histocompatibility complex, class II, DM alpha (HLA-DMA)
Involved in MHC Class II antigen 
presentation -3.04 7.7E-04
NM_000246 Class II, major histocompatibility complex, transactivator (CIITA)
Controls expression of MHC class II 
genes -3.39 2.6E-03




TI induced genes involved in immunosuppression 
TI also produced an increase in expression of genes associated with immunosuppression 
or tolerance (Table 8).  Indoleamine, an enzyme involved in the catabolism of tryptophan, 
is known to be expressed by DC and promotes tolerance through the suppression of T cell 
responses and expansion of T regulatory cells (53, 54).  Indoleamine was up-regulated 
after TI 84.69 fold, P=3.9E-07.  Another closely related immunosuppressive gene, 
kynurenine, whose expression is thought to induce tolerogenic DC (55), was up-regulated 
3.79 fold, P=2.9E-06.  IL-10, an immunosuppressive cytokine that modulates DC 
maturation and favors the differentiation of tolerogenic DC (56) was up-regulated 11.27 














Accession no. Description Function
(Genbank)
Immunosupressive genes TI/Leuk P-value
M34455 Indoleamine Suppresses T cell response, promotes tolerance 84.69 3.9E-07
AI074145 Kynurenine Expression induces tolerogenic DC 3.79 2.9E-06
NM_000572 Interleukin 10 Induces DC "exhaustion", transiently inhibits mature DC 11.27 9.8E-06
Fold change after TI
CTCL + GVHD
Table 8. Up-regulation of Immunosuppressive genes after TI.                 
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline.  RNA 
was isolated from the CD4- cell fraction from 3 CTCL patients and 3 GVHD patients following 
leukapheresis and after ECP + overnight incubation (TI).  All samples were processed identically 
and array data from 6 patients was analyzed using GeneSpring software to identify differentially 
expressed genes.  Because of the similar patterns in gene expression we were able to combine the 
CTCL + GVHD data sets. The fold changes in this table represent combined data from all 6 
patients.  P-values are listed.
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TI induces genes involved in cell adhesion 
After TI treatment, there was significant up-regulation of genes involved in cell adhesion 
(Table 9).  Adhesion molecules play an important role in the function of DC, allowing for 
cell migration and interaction with T lymphocytes (57)  Increased expression of certain 
adhesion molecules, such as integrins and matrix metalloproteases, is induced upon DC 
maturation, allowing DC to disengage from the extracellular matrix, cross basement 
membranes, and travel to draining lymph nodes to activate T cells (58).  Several members 
of the integrin family were up-regulated after TI, including integrin beta 8 (144.84 fold, 
P=1.7E-07), which activates TGFbeta (59), integrin alpha 5 (component of fibronectin 
receptor, 3.32 fold, P=1.2E-05) (60), and integrin alpha V (component of vitronectin 
receptor 5.57 fold, P=1.2E-05) (61).  In addition, TI increased transcript levels of 
osteopontin (304.27 fold, P=1.7E-07), which regulates cytokine production in dendritic 
cells and induces DC with a Th1-promoting phenotype (62).  Delta-1 catenin, a protein 
which is linked to the cytopasmic domain of transmembrane cadherin proteins (63), was 
also up-regulated after TI (4.84 fold, P=6.5E-04).  In addition, ICAM1, which plays a 
role in DC interaction with T cells (64) was induced (3.78 fold, P=3.1E-03).  Several 
matrix metalloproteases (MMP) were up-regulated after TI, including: MMP1 (101.58 
fold, P=6.4E-03), which modulates sustained integrin mediated signals (65); MMP9 
(34.58 fold, P=7.0E-05), which is more highly expressed in mature DC and regulates DC 
migration (66); as well as MMP14 (39.92 fold, P=4.3E-07) and MMP19 (117.04 fold, 

















Analysis of genes unique to CTCL and GVHD 
Despite the similarities in the majority of genes, the population of genes that is 
differentially regulated after TI is also of interest, particularly because this therapy 
induces different clinical responses CTCL and GVHD patients.  Therefore, we also 
analyzed the 40% of the genes that were unique to CTCL and GVHD patients and found 
important differences. Since these genes are unique to CTCL patients and were 
unchanged in GVHD patients, analysis of these different genes may provide us with 
insight into how TI stimulates anti-tumor immune responses.   
 
In CTCL patients, there was significant up-regulation of many stress related genes 
that promote inflammatory or immunostimulatory responses (Table 10).  The aryl-
Accession no. Description Function
(Genbank)
Cell adhesion molecules TI/Leuk P-value
BF513121 Integrin beta 8 Activates TGFbeta 148.84 1.7E-07
NM_002205 Integrin alpha 5 Component of fibronectin receptor 3.32 1.2E-05
AI093579 Integrin alpha V Component of vitronectin receptor 5.57 1.2E-05
M83248 Osteopontin Regulates cytokine production in dendritic cells 304.27 1.7E-07
NM_001331 Delta-1 catenin Linked to cytoplasmic domain of transmembrane cadherin proteins 4.84 6.5E-04
NM_000201 ICAM1 Mediates DC interaction with T cells 3.78 3.1E-03
Matrix metalloproteases
NM_002421 MMP1 Modulates sustained integrin mediated signals 101.58 6.4E-03
NM_004994 MMP9 Mature DC express more MMP9 than immature DC, plays role in migration 34.58 7.0E-05
AU149305 MMP14 Degradation of extracellular matrix, cell migration 39.92 4.2E-07
U38321 MMP19 Degradation of extracellular matrix, cell migration 117.04 6.9E-08
Fold change after TI
CTCL + GVHD
Table 9. Up-regulation of genes involved in cell adhesion after TI.         
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline.  RNA 
was isolated from the CD4- cell fraction from 3 CTCL patients and 3 GVHD patients following 
leukapheresis and after ECP + overnight incubation (TI).  All samples were processed identically and 
array data from 6 patients was analyzed using GeneSpring software to identify differentially expressed 
genes.  Because of the similar patterns in gene expression we were able to combine the CTCL + GVHD 
data sets. The fold changes in this table represent combined data from all 6 patients.  P-values are listed.
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hydrocarbon receptor nuclear translocator 2, which is a transcription factor increased 
during cellular stress (68), was up-regulated in CTCL patients 23.44 fold, P=1.1E-02.  
Many heat shock proteins (HSPs) were up-regulated after TI only in CTCL patients. 
HSPs are “danger signals” that play an important role in DC differentiation, particularly 
in the generation of immunostimulatory DC (69).  HSP70-2 (8.75 fold, P=2.2E-02), is 
expressed in response to stress stimuli and free radials (70).  HSP27 (4.49 fold, P=5.3E-
03) and HSP40 (4.09 fold, P=6.2E-03) are protective and inhibit oxidative stress induced 
damage (71).  Stress-induced-phosphoprotein 1, a protein that modulates interactions 
between HSP70 and HSP90 (72), was up-regulated 3.47 fold, P=2.3E-02 after TI.  Gene 
expression of HSP70, a protein that stimulates generation of antigen-specific cytotoxic T 
cell responses when bound to endogenous peptides presented on MHC class I (73), was 
up-regulated 2.75 fold, P=3.6E-03.  Activator of HSP90, which stimulates the intrinsic 
activity of HSP90 (74), was up-regulated 2.72 fold, P=2.8E-02.  Heat-shock transcription 
factor 2, responsible for activating HSP genes in response to stress (75), was induced 
2.21 fold in CTCL patients, P=4.7E-04.  Heat-shock associated protein 1, which binds 
HSP27, and HSP0, a stress-induced chaperone, were up-regulated 2.10 fold and 2.09 






















In CTCL patients, there were many DC-related genes that were induced after TI 
(Table 11).  CD205, or DC- SIGN, a DC-specific C-type lectin that mediates DC 
adhesion with T cells (77), was up-regulated 5.57 fold, P=2.5E-02 in CTCL patients after 
TI.  Thymic stromal lymphopoietin receptor, a transmembrane protein expressed in 
activated DC (78), was up-regulated 5.04 fold, P=9.7E-03.  A gene important for antigen 
processing in DC, cathepsin V (79), was induced 3.78 fold, P=1.1E-02.  Fas ligand, 
which mediates direct killing of cancer cells by DC (80), was up-regulated 2.56 fold, 
although the P value did not reach significance.  CD163, a scavenger receptor (81), was 
non-significantly up-regulated 2.27 fold.  CD86, an important co-stimulatory molecule 
expressed on DC (35), was up-regulated only in CTCL patients, 2.14 fold, although P-
Accession no. Description Function
(Genbank) TI/Leuk P-value TI/Leuk P-value
Stress related genes
NM_014862 Aryl-hydrocarbon receptor nuclear translocator 2
Transcription factor increased 
during hypoxia 23.44 1.1E-02 No Change -
NM_005346 Heat-shock protein 70-2 Expressed in response to stress stimuli, free radicals 8.75 2.2E-02 No Change -
NM_001540 Heat-shock protein 27 Inhibits oxidative stress induced damage, augments AKT activation 4.49 5.3E-03 No Change -
BC031044 Heat-shock protein 40, subfamily A, member 4
Confers resistance to oxidative 
stress 4.09 6.2E-03 No Change -
AL553320 Stress-induced-phosphoprotein 1 Hsp70/Hsp90 organizing protein 3.47 2.3E-02 No Change -
BC002526 Heat-shock protein 70 Involved in stress response 2.75 3.6E-03 No Change -
NM_012111 Activator of Hsp90 (AHSA1)
Stimulates intrinsic activity of 
Hsp90 2.72 2.8E-02 No Change -
M65217 Heat-shock transcription factor 2
Activates heat-shock response 
genes under stress 2.21 4.7E-04 No Change -
NM_024610 Heat-shock associated protein 1
Binds to Hsp27, regulates stress 
response 2.10 NS No Change -
NM_002157 Heat-shock protein 10 Stress-induced chaperone 2.09 NS No Change -
Fold change after TI
CTCL GVHD
Table 10.  Stress related genes only up-regulated in CTCL patients                                      
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline.  RNA 
was isolated from the CD4- cell fraction from 3 CTCL patients and 3 GVHD patients following 
leukapheresis and after ECP + overnight incubation (TI).  All samples were processed identically 
and array data from 6 patients was analyzed using GeneSpring software to identify differentially 
expressed genes.  P-values are listed.  NS signifies “non-significant” and is listed in place of a P-
value for genes where P is greater than 0.05.
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value did not reach significance.  Two DC-associated proteins involved in the ability of 
DC to stimulate CD4 T cells were down-regulated: dendritic cell-associated lectin, -2.22 
fold, P not significant, and CD83, -2.80 fold, P=4.0E-03 (82, 83).  Also down-regulated 




















Accession no. Description Function
(Genbank) TI/Leuk P-value TI/Leuk P-value
DC related genes
AF290886 CD209 (DC-SIGN) Novel DC-specific C-type lectin, mediates adhesion with T cells 5.57 2.5E-02 No Change -
NM_022148
Thymic stromal 
lymphopoietin receptor  
(CRLF2)
Transmembrane protein expressed 
by activated DC 5.04 9.7E-03 No Change -
AF070448 Cathepsin L2 Encodes cathepsin V, involved in antigen presentation 3.78 1.1E-02 No Change -
D38122 Fas ligand Involved in direct kiling by DC 2.56 NS No Change -
NM_004244 CD163 molecule Scavenger receptor 2.27 NS No Change -
NM_006889 CD86 molecule Co-stimulatory molecule expressed on DC 2.14 NS No Change -
AW237307 Dendritic cell-associated lectin-1
Expressed on DC, interacts with 
CD4 T cells -2.22 NS No Change -
NM_004233 CD83 molecule Expressed on DC, involved in CD4 T cell generation -2.80 4.0E-03 No Change -
Toll-like receptors
AF245702 Toll-like receptor 7 Down-regulated in mature DC, Pro-inflammatory signaling -9.00 1.2E-02 No Change -
AW665250 Toll-like receptor 10 Down-reg in mature DC, activates transcritpion through MyD88 -4.41 1.0E-03 No Change -
NM_003266 Toll-like receptor 4 Down-reg in mature DC, Receptor for LPS -2.70 NS No Change -
Disease related
NM_005032 Plastin 3 (T isoform) Overexpressed in PBMCs of CTCL patients 4.90 NS No Change -
Cell survivial/apoptosis
NM_002775 HtrA serine peptidase 1 Tumor suppressor, promotes cell death 31.29 6.2E-03 No Change -
NM_022121 PERP, TP53 apoptosis effector
Plays role in cellular adhesion and 
survival 9.45 1.1E-03 No Change -
AI912351 Nucleolar protein 3 Inhibits apoptosis 3.73 4.2E-03 No Change -
AF229253 Apoptosis inhibitor 5 Antiapoptosis 2.86 NS No Change -
Cell adhesion 
NM_013231 Fibronectin leucine rich transmembrane protein 2 Cell adhesion receptor signaling 39.84 1.4E-03 No Change -
NM_018204 Cytoskeleton associated protein 2
Involved in cytoskeleton and 
cytokinesis 3.34 2.0E-03 No Change -
NK cell related genes
AF276292 NK cell Ig-like receptor 4 Receptor on natural killer cells 3.83 NS No Change -
Fold change after TI
CTCL GVHD
Table 11.  Genes differentially expressed only in CTCL patients 
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline.  RNA 
was isolated from the CD4- cell fraction from 3 CTCL patients and 3 GVHD patients following 
leukapheresis and after ECP + overnight incubation (TI).  All samples were processed identically and 
array data from 6 patients was analyzed using GeneSpring software to identify differentially expressed 
genes.  P-values are listed.  NS signifies “non-significant” and is listed in place of a P-value for genes 
where P is greater than 0.05.
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TLRs are known to be down-regulated in mature DC as compared to immature 
DC (84).  TLR7 was down-regulated -9.00 fold, P=1.2E-02; TLR10 -4.41 fold, P=1.1E-
03; and TLR4, a receptor for LPS (84), was down-regulated -2.70 fold, although P-value 
did not reach significance.   
 
A gene specifically related to CTCL and known to be over-expressed in 
peripheral blood mononuclear cells of CTCL patients, plastin-T (85), was up-regulated 
only in CTCL patients after TI  4.90 fold, P-value non-significant (Table 11).  Genes 
mediating cell survival and apoptosis specific to CTCL patients included: HtrA serine 
peptidase 1, a tumor suppressor and promoter of cell death (86), up-regulated 31.29 fold, 
P=6.2E-03; PERP, a protein that plays a role in both cell adhesion and survival (87), 9.45 
fold, P=1.1E-03.  Also two inhibitors of apoptosis, nucleolar protein 3 (88) and apoptosis 
inhibitor 5 (89), were up-regulated 3.73 fold, P=4.2E-03 and 2.86 fold, P non-significant, 
respectively.  Genes involved in cell adhesion, such as the fibronectin leucine rich 
transmembrane protein 2, which plays a role in cell adhesion receptor signaling (39.84 
fold, P=1.4E-03), and cytoskeleton associated protein 2, involved in the cytoskeleton and 
cytokinesis (3.34 fold, P=2.0E-03) were up-regulated in CTCL patients after TI (90, 91).  
Finally, a receptor found on natural killer T cells (NK cells), the NK cell Ig-like receptor 





























Accession no. Description Function
(Genbank) TI/Leuk P-value TI/Leuk P-value
DC related genes
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NM_022148
Thymic stromal 
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Transmembrane protein expressed 
by activated DC 5.04 9.7E-03 No Change -
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NM_006889 CD86 molecule Co-stimulatory molecule expressed on DC 2.14 NS No Change -
AW237307 Dendritic cell-associated lectin-1
Expressed on DC, interacts with 
CD4 T cells -2.22 NS No Change -
NM_004233 CD83 molecule Expressed on DC, involved in CD4 T cell generation -2.80 4.0E-03 No Change -
Toll-like receptors
AF245702 Toll-like receptor 7 Down-regulated in mature DC, Pro-inflammatory signaling -9.00 1.2E-02 No Change -
AW665250 Toll-like receptor 10 Down-reg in mature DC, activates transcritpion through MyD88 -4.41 1.0E-03 No Change -
NM_003266 Toll-like receptor 4 Down-reg in mature DC, Receptor for LPS -2.70 NS No Change -
Disease related
NM_005032 Plastin 3 (T isoform) Overexpressed in PBMCs of CTCL patients 4.90 NS No Change -
Cell survivial/apoptosis
NM_002775 HtrA serine peptidase 1 Tumor suppressor, promotes cell death 31.29 6.2E-03 No Change -
NM_022121 PERP, TP53 apoptosis effector
Plays role in cellular adhesion and 
survival 9.45 1.1E-03 No Change -
AI912351 Nucleolar protein 3 Inhibits apoptosis 3.73 4.2E-03 No Change -
AF229253 Apoptosis inhibitor 5 Antiapoptosis 2.86 NS No Change -
Cell adhesion 
NM_013231 Fibronectin leucine rich transmembrane protein 2 Cell adhesion receptor signaling 39.84 1.4E-03 No Change -
NM_018204 Cytoskeleton associated protein 2
Involved in cytoskeleton and 
cytokinesis 3.34 2.0E-03 No Change -
NK cell related genes
AF276292 NK cell Ig-like receptor 4 Receptor on natural killer cells 3.83 NS No Change -
Fold change after TI
CTCL GVHD
Table 11.  Genes differentially expressed only in CTCL patients 
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline.  RNA 
was isolated from the CD4- cell fraction from 3 CTCL patients and 3 GVHD patients following 
leukapheresis and after ECP + overnight incubation (TI).  All samples were processed identically and 
array data from 6 patients was analyzed using GeneSpring software to identify differentially expressed 
genes.  P-values are listed.  NS signifies “non-significant” and is listed in place of a P-value for genes 
where P is greater than 0.05.
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There was also a group of genes that were only differentially expressed in GVHD 
patients (Table 12 and 13).  Analysis of these GVHD specific genes revealed the 
following genes of interest.  Various immune response mediators were specifically up-
regulated in GVHD patients after TI (Table 12).  Interleukin 19, a transcriptional 
activator of the immunosuppressive cytokine IL-10 (93), was up-regulated 50.88 fold, P-
value non-significant after TI.  CXCL11, an interferon-gamma inducible T cell 
chemoattractant (94), was non-significantly up-regulated after TI 26.14 fold.  In addition, 
an enzyme closely related to indoleamine named tryptophan 2,3-dioxygenase (TDO2), 
which is also a rate-limiting enzyme in the catabolism of tryptophan (95), was up-
regulated 22.53 in GVHD patients after TI, although P-value did not reach significance.  
A member of the TNF receptor superfamily (member 11a), which functions as an 
activator of NFkB (96), was up-regulated 9.00 fold, P=3.8E-02.  A transcription factor 
that plays a negative regulatory role in TLR signaling pathways, called activating 
transcription factor 3 (97), was up-regulated 4.74 fold, P=2.0E-02.  TNFalpha-induced 
protein 2, which is induced  by inflammatory mediators such as TNF, IL-1B, and LPS 
(98), was up-regulated 3.29 fold, P=5.8E-03.  Two pro-inflammatory cytokines were 
regulated in opposite directions in GVHD and CTCL patients.  Interleukin-8 was up-
regulated in GVHD patients 3.03 fold, P=3.1E-02 and was down-regulated in CTCL 
patients -2.31 fold, P-value non-significant.  Interferon-gamma, on the other hand, was 
down-regulated in GVHD patients (-4.52 fold, P non-significant) and up-regulated in 
CTCL (3.14 fold, P non-significant).  A component of complement (C1q binding 
protein), which inhibits TLR0induced IL-12 production (99), was down-regulated after 
















In GVHD patients there was differential expression of many DC-related genes 
(Table 13).  Fibronectin, which has been shown to be up-regulated in DC induced by 
GM-CSF and IL-4 in other microarray studies (100), was up-regulated in our study 92.08 
fold, although P-value did not reach significance.  Tapasin, a protein involved in MHC 
class I antigen presentation (101), was up-regulated in GVHD patients 3.86 fold, P=3.2E-
02 after TI.  CD40, a molecule involved in DC survival and cytokine secretion (37), was 
up-regulated 3.81 fold, P=1.5E-02.  Rel-B, which binds NfKB and plays a major role in 
NFkB signaling (102), was up-regulated 3.27 fold, P=1.5E-04.  FLT3, which is induced 
on DC maturation (103), binds FLT3L, which is used to mature DC (104).  FLT3 was 
down-regulated in GVHD patients after TI, -9.09 fold, P=4.0E-03.  Several genes 
Accession no. Description Function
(Genbank) TI/Leuk P-value TI/Leuk P-value
Immune response mediators
NM_013371 Interleukin 19 Transcriptional activator of IL-10 No Change - 50.88 NS
AF002985 CXCL11 IFN-gamma inducible T cell chemoattractant No Change - 26.14 NS
NM_005651 Tryptophan 2,3-dioxygenase (TDO2)
Rate-limiting enzyme in 
tryptophan catabolism, closely 
related to IDO
No Change - 22.53 NS
AW026379 TNF receptor superfamily, member 11a Activator of NFkB No Change - 9.00 3.8E-02
AB066566 Activating transcription factor 3
Negative regulatory transcription 
factor in TLR pathways No Change - 4.74 2.0E-02
NM_006291 TNFalpha-induced protein 2 Induced by TNF, IL-1B, LPS No Change - 3.29 5.8E-03
AF043337 Interleukin 8 Pro-inflammatory cytokine -2.31 NS 3.03 3.1E-02
M29383 Interferon gamma Pro-inflammatory, activates NFkB 3.14 NS -4.52 NS
L04636 Complement component 1, q subcomponent binding protein
Inhibits TLR4-induced IL-12 
production No change - -2.63 4.8E-02
Fold change after TI
GVHDCTCL
Table 12.  Immune response genes differentially expressed in GVHD patients                                         
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline.  RNA 
was isolated from the CD4- cell fraction from 3 CTCL patients and 3 GVHD patients following 
leukapheresis and after ECP + overnight incubation (TI).  All samples were processed identically and 
array data from 6 patients was analyzed using GeneSpring software to identify differentially expressed 
genes.  P-values are listed.  NS signifies “non-significant” and is listed in place of a P-value for genes 
where P is greater than 0.05.
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involved in cell survival and apoptosis were differentially expressed in GVHD patients.  
The programmed cell death 6 receptor repressor, which is part of the apoptotic machinery 
controlled by the T cell receptor (105), was up-regulated 28.45 fold, P=1.6E-02.  Tax1 
binding protein, which inhibits TNF-induced apoptosis (106), was up-regulated 2.61 fold, 
P=2.0E-02.  BCL2-associated athanogene, which enhances the anti-apoptotic effects of 
BCL2, a protein involved in DC survival (107), was up-regulated 2.33 fold, P=4.5E-02.  
BCL2-interacting protein, however, which protects against cell death (108), was down-
regulated -3.44 fold, P=2.2E-02.  Genes important in cell adhesion, such as TRAF2 and 
NCK interacting kinase, involved in cytoskeleton regulation (109), and CD226 molecule, 
an intercellular adhesion molecule (110), were down-regulated after TI in GVHD, -7.8 
fold, P=6.6E-03 and -5.35 fold, P=8.8E-04, respectively.  In GVHD patients, several 
genes encoding NK cell receptors, which regulate the function of NK cells (92), were 
down-regulated.  Killer cell lectin-like receptor subfamily C members 1 (-5.32 fold, 
P=2.6E-02), 2 (-2.37 fold, P=3.9E-02), and 3 (-2.40 fold, P=1.2E-02) were all down-






























qRT-PCR confirmation of microarray data 
The expression of selected differentially expressed genes was confirmed by qRT-PCR 
using aliquots of the same RNA samples used for the microarrays (Figure 2).  Despite the 
important differences in gene expression between patient groups, we chose to verify DC-
Accession no. Description Function
(Genbank) TI/Leuk P-value TI/Leuk P-value
DC-related genes
BC005858 Fibronectin Up-regulated in DC induced by GM-CSF + IL-4 No Change - 92.08 NS
AF067286 TAP binding protein (tapasin) Involved in MHC class I antigen presentation No Change - 3.86 3.2E-02





Up-regulated in activated DC, 
binds NFkB No Change - 3.27 1.5E-04
NM_004119 FLT3 (fms-related tyrosine kinase 3)
Induced on DC maturation, 
FLT3L is used to mature DC No change - -9.09 4.0E-03
Cell survival/apoptosis
AB033060 Programmed cell death 6 receptor repressor
Part of apoptotic machinery 
controlled by T cell receptor No Change - 28.45 1.6E-02
AK001327 Tax1 (human T-cell leukemia virus type I) binding protein 3 Inhibits TNF-induced apoptosis No Change - 2.61 2.0E-02
AF116273 BCL2-associated athanogene Enhances anti-apoptotic effects of BCL2 No Change - 2.33 4.5E-02
U15172 BCL2/adenovirus E1B 19kDa interacting protein 1 Protects against cell death No change - -3.44 2.2E-02
Cell adhesion 
AF172268 TRAF2 and NCK interacting kinase
Involved in cytoskeleton 
regulation No change - -7.88 6.6E-03
NM_006566 CD226 molecule Intercellular adhesion molecule No change - -5.35 8.8E-04
NK cell related genes
NM_002260 Killer cell lectin-like receptor subfamily C, member 1 Regulates function of NK cells No change - -5.32 2.6E-02
AF022048 Killer cell lectin-like receptor subfamily C, member 3 Regulates function of NK cells No change - -2.40 1.2E-02
L76666 Killer cell lectin-like receptor subfamily C, member 2 Regulates function of NK cells No change - -2.37 3.9E-02
GVHDCTCL
Fold change after TI
Table 13.  Genes differentially expressed only in GVHD patients 
Fold change in gene expression after TI, using the leukapheresis (Leuk) sample as a baseline.  RNA 
was isolated from the CD4- cell fraction from 3 CTCL patients and 3 GVHD patients following 
leukapheresis and after ECP + overnight incubation (TI).  All samples were processed identically and 
array data from 6 patients was analyzed using GeneSpring software to identify differentially expressed 
genes.  P-values are listed.  NS signifies “non-significant” and is listed in place of a P-value for genes 
where P is greater than 0.05.
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related genes that were similarly differentially expressed in CTCL and GVHD patients to 
validate the accuracy of our microarray data and to confirm the similarity of the changes 
in gene expression in these two patient groups.  The qRT-PCR results correlated with the 
microarray results for all 4 selected genes (DC-LAMP, Indoleamine, CCR7, and CD14).  
Figure 2 shows the average transcriptional changes in these 4 selected genes across 













































































































   

























Figure 2:  Quantitative RT-PCR confirmation of microarray data.
Fold expression of selected genes after ECP and TI relative to Leuk (control) expression levels.  
Data represents average fold change across 5 patients, error bars are standard error of the mean.  (A)
DC-LAMP was up-regulated 1.9± 0.3 fold in ECP vs Leuk samples and 226.5± 50.4 fold (P-value 
0.008) in TI vs Leuk.  (B) Indoleamine was unchanged after ECP and up-regulated 85.62± 26.6
fold after TI (P-Value 0.008). (C) CCR7 was up-regulated 1.60± 0.6 fold after ECP and 3.76± 1.4
fold after TI (P-value 0.01). (D) CD14 was down-regulated 1.3± 0.06 fold in ECP vs Leuk samples 














































To verify that 1) the gene expression changes in these selected genes were taking place in 
the monocyte/DC population, and 2) that the leukapheresis sample was an appropriate 
baseline, we repeated this real-time PCR using patient samples that were depleted of 
CD4, CD8, CD19 positive cell fractions to enrich for the monocyte/DC population and 
had a pre-treatment peripheral blood draw as a baseline for gene expression levels.  
Samples (including new pre-treatment samples) from 4 patients undergoing ECP were 
treated with triple bead depletion of non-monocyte populations and RNA was isolated 
and qRT-PCR performed on 2 genes of particular interest (DC-LAMP, CD14).  The 
observed gene expression trend in DC-LAMP and CD14 in these 4 patient samples 
confirms the microarray data and validates the use of the leukapheresis sample as a 
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Figure 3 . Further qRT-PCR confirmation of microarray data using CD4, CD8, CD19 
depleted samples from patients undergoing ECP.
Fold expression of selected genes after Leukapheresis, ECP, O/N incubation of pre-treatment 
sample, O/N incubation of leukapheresis sample, and O/N incubation of ECP (TI) relative to pre-
treatment whole blood (control) expression levels.  Data represents average fold change across 4 
patients for graph A, and 3 patients for graph B.  Error bars are standard error of the mean.  (A) DC-
LAMP was up-regulated 19.1 fold in Pre Day 1 samples, 121.6 ± 43.6 fold in Leuk Day 1 samples, 
and 153.58 ± 69.58 in TI treated samples.  The trend towards upregulation did not reach 
significance.  (B) CD14 was down-regulated after TI 1.5± 0.2 fold, demonstrating a downward 









































































qRT-PCR validation of gene expression in normal controls  
In order to verify that the induction of a mature DC gene expression profile after TI was 
not unique to CTCL and GVHD patients, we used qRT-PCR to study gene expression 
changes in TI-treated samples from healthy normal control leukapheresis donors.  The 
transcriptional changes in 2 selected genes (DC-LAMP and CD86) were verified as 
shown in Figure 4, with similar TI-induced changes in gene expression as seen in patient 













In addition, the time course of differential gene expression for selected genes (DC-
LAMP, CD80, CD40, and GPNMB) was clarified through the analysis of transcript 
levels at several different time points during the ECP and TI procedure.  This more 
detailed analysis was made possible by the use of a bench-top ECP apparatus, which is an 
Figure 4:  G ene expression changes in normal control samples after leukapheresis and 
bench-top ECP and TI procedures.                                      
Fold expression of selected genes after a donated leukapheresis sam ple w as treated with 
bench-top ECP apparatus (ECP sam ple underw ent 3 hours of 8-M OP + UVA exposure) and 
subsequently incubated overnight (TI sam ple).  The pre-treatm ent sam ple is used as 
baseline.  D ata represents average fold change across 3 healthy norm al control individuals, 
error bars are standard error of the m ean.  (A) DC -LAM P was up-regulated 1.3± 0.4 fold in 
ECP vs Pre Day 0 sam ples and 46.67± 9.9 fold (P-value 0.01) in TI vs Pre Day 0. (B) CD86 
was unchanged after EC P and up-regulated 6.28± 2.4 fold after T I, although the P-value did 


















































































open access system allowing for acquisition of samples throughout the duration of the 
ECP procedure.  The following samples were obtained from the normal control donors: 
1) leukapheresis sample (baseline), 2) 1 hour ECP, 3) 2 hours ECP, and 4) 3 hours ECP.  
Half of each of these samples was incubated overnight (O/N), giving the following 
additional samples: 6) Leukapheresis O/N, 7) 1 hour ECP O/N, 8) 2 hour ECP O/N, 9) 3 
hour ECP O/N, and 10) Transimmunization (TI), which was treated with the 3 hours of 
ECP and then cultured O/N in a 1 liter platelet storage bag.  Not only did the gene 
expression changes in the monocyte population of normal controls correlate with the 
microarray findings, but also the transcript kinetics during this bench-top ECP procedure 
verified that the established TI procedure (ECP + overnight incubation of treated cells in 
a platelet storage bag) induces the largest and most significant gene expression changes 





































Figure 5 . Confirmation of gene expression changes in normal control leukapheresis donors
Fold expression change of selected genes in a representative normal control donor.  This healthy 
individual underwent leukapheresis, which was treated with the TI procedure with samples taken at 
specific time-points.  Fold change of selected genes (DC-LAMP, CD80, CD40, GPNMB) was 
measured using a pre-treatment whole blood sample as the baseline and is shown at the following 
time-points: immediately after leukapheresis aquisition (Leuk D0), after 1 hour of ECP treatment (1 
hr D0), 2 hours ECP (2 hr D1), 3 hours ECP (3 hr D0), after overnight (O/N) incubation of the pre-
treatment sample (Pre D1), O/N incubation of the leukapheresis (Leuk D1), 1 hour ECP sample 
incubated O/N (1 hr D1), 2 hours ECP sample O/N (2 hr D1), 3 hours ECP O/N (3 hr D3), and 
finally, after the full TI procedure including O/N culture in a platelet storage bag (Bag O/N).  (A)
DC-LAMP showed a trend of up-regulation during ECP + O/N incubation, with the most 
impressive increase in transcript (a 63.4 fold increase) occurring after TI.  (B) CD80 also showed a 
trend of up-regulation.  After TI we saw a 28.2 fold increase, which was the largest in any sample.  
(C) There was a slight increase in CD40 expression after 3 hours of ECP treatment and also in the 2 
hr ECP O/N, 3 hr ECP O/N, and TI-treated samples.  After TI the fold change was 1.6. (D) For 
GPNMB, a newly identified gene expressed in mature DC, we saw an increase in gene expression 
after overnight incubation, with the highest fold change occurring in the 2 hr D1 sample (up-
regulated 3358.0 fold).  After TI GPNMB was up-regulated 1069.0 fold, which correlates with our 
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Pathway analysis using GeneGo   
To identify pathways relevant to ECP and TI, we used MetaCore Software (GeneGo Inc, 
St Joseph, MI).  This is a proprietary, manually curated database containing 
approximately 500 canonical signaling and metabolic pathways.  After TI, there were 71 
significantly involved pathways (P≤0.05).  The 20 most significantly involved signaling 
pathways after TI are listed in Table 14.  Several pathways related to regulation of 
apoptosis and cell cycle were significantly involved after TI. Given the degree of ex vivo 
manipulation of TI-treated cells, it seemed logical that genes related to apoptosis and cell 
survival would be affected by the TI procedure.  There were 3 anti-apoptotic or pro-
survival pathways significantly involved after TI: the anti-apoptotic TNFs/NFkB/Bcl-2 
pathway, the AKT signaling pathway, and the anti-apoptotic TNFs/NFkB/IAP pathway.  
There are several other highly significantly involved pathways that are of particular 
interest.  The chemokines and adhesion pathway was the only signaling pathway that was 
significantly involved after TI and importantly, also significantly involved after ECP 
(Table 15).  The fact that this is the only signaling pathway that is significantly involved 
in both treatments emphasizes its potential importance.  Activation of pathways related to 
modulation of the immune response, such as the alternative complement pathway and 
signaling mediated by IL-6 and IL-1 also occurred after TI (Table 14).  Table 15 lists all 
the pathways that were significantly involved after ECP (12 significantly involved 
pathways in total).  The RalA and RalB pathways, both highly significantly involved, 
play a role in chemotaxis and endocytosis, two important cell processes for newly 
activated DC.  In addition to significant involvement of the chemokines and adhesion 
pathway, the more-specific integrin-mediated cell adhesion pathway is involved in the 
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mechanism of ECP.  Taken together, the involvement of the chemokines and adhesion 
pathway in both TI and ECP as well as the involvement of integrin-mediated cell 
adhesion in ECP suggest that cell adhesion may initiate signaling cascades that could 
play an important role in the mechanism of both of these therapies. Because GeneGo 
software analyzes entire signaling networks, it is possible that the genes involved in the 
chemokines and adhesion pathway after ECP represent changes in gene expression that 
occur initially upon integrin binding, whereas the changes in gene expression that occur 

















Table 14. List of 20 most significantly involved pathways after TI treatment.                     
GeneGo software was used to identify most significantly involved pathways in TI treatment.  This 
pathway data was generated by uploading a gene list of all differentially expressed genes (combined 
data from 3 CTCL and 3 GVHD patients) with a fold change greater than or equal to 2 and P less 
than or equal to 0.05 after TI.  The total number of genes in each GeneGo signaling pathway is listed, 
as is the number of pathway genes that were differentially expressed in our microarray data.  The P-
value represents the probability of having the observed number of differentially expressed genes on a 
given pathway by chance.  
GeneGo Pathway Name Total number of genes in pathway
Number of differentially 
expressed genes in 
pathway
P-Value
Apoptotic TNF-family pathways 40 20 1.3E-05
ATM/ATR regulation of G1/S checkpoint 42 20 3.1E-05
WNT signaling pathway 28 14 2.5E-04
Chemokines and adhesion 174 53 2.8E-04
Anti-apoptotic TNFs/NFkB/Bcl-2 pathway 42 18 4.0E-04
Putative SUMO-1 pathway 29 14 4.1E-04
TNFR1 signaling pathway 47 19 6.8E-04
Fas signaling cascades 44 18 7.9E-04
Transcription regulation of amino acid metabolism 41 17 9.2E-04
AKT signaling 57 21 1.5E-03
TPO signaling via Jak-Stat pathway 23 11 1.9E-03
Alternative complement pathway 23 11 1.9E-03
Brca1 as transcriptional regulator 30 13 2.3E-03
Activation of PKC via G-Protein coupled receptor 87 28 3.0E-03
JNK pathway 45 17 3.0E-03
N-Glycan biosynthesis p2 21 10 3.1E-03
Sialic-acid receptors (Siglecs) signaling 12 7 3.2E-03
Anti-apoptotic TNFs/NFkB/IAP pathway 31 13 3.2E-03














Figure 6 shows the pathway map of the Chemokines and Adhesion Pathway.  This 
diagram, generated by the GeneGo Software Program, shows all of the genes involved in 
this pathway and also demonstrates which of these genes are up or down regulated in our 









GeneGo Pathway Name Total number of genes in pathway
Number of differentially 
expressed genes in 
pathway
P-Value
RalB regulation pathway 14 3 6.2E-04
Insulin regulation of glycogen metabolism 57 4 5.4E-03
IL9 signaling pathway 33 3 7.8E-03
RalA regulation pathway 35 3 9.1E-03
EPO-induced Jak-STAT pathway 37 3 1.1E-02
Glycolysis and gluconeogenesis 13 2 1.1E-02
cAMP signaling 115 5 1.4E-02
PDGF activation of prostacyclin synthesis 18 2 2.1E-02
Chemokines and adhesion 174 6 2.1E-02
Visual perception 19 2 2.3E-02
Integrin-mediated cell adhesion 92 4 2.7E-02
IL-10 signaling pathway 23 2 3.3E-02
Table 15. List of significantly involved pathways after ECP treatment.    
GeneGo software was used to identify significantly involved pathways after ECP treatment. This 
pathway data was generated by uploading a gene list of all differentially expressed genes (combined 
data from 3 CTCL and 3 GVHD patients) with a fold change greater than or equal to 2 and P less than 
or equal to 0.05 after ECP.  The total number of genes in each GeneGo signaling pathway is listed, as 
is the number of pathway genes that were differentially expressed in our microarray data.  The P-value 





















 Figure 7 shows another pathway that is significantly involved in TI: the AKT Signaling 
Pathway.  This pathway is thought to play a role in cell survival, particularly in the 
survival of DC (111).  A recently published study used GeneGo Software to analyze the 
transcriptional networks involved in DC stimulated with TLR7 agonists (112).  
Researchers saw induction of anti-apoptotic pathways such as those involving NFkB and 
BCL2, as well as involvement of chemokine signaling networks (112).   Unfortunately, it 
Figure 6:  Chemokines and adhesion signaling pathway.                                
Pathway map shows all genes involved in chemokines and adhesion pathway as well as marking 
genes involved in pathway that were significantly up or down regulated in our data.  The map 
was generated by uploading the microarray data (combined data set for all 6 patients) into 
GeneGo Software for pathway analysis.  Thermometers indicate amount of differential gene 
expression for TI vs Leuk.  Red thermometers indicate level of up-regulation, blue thermometers 
indicate level of down-regulation.  Cell adhesion and activation of certain integrins and cell 




is difficult to directly compare our pathway data to the data published in this other study 
(112), as the focus of that study was on transcription regulatory networks and protein-
interaction networks, and not canonical signaling pathways (112). 
Figure 7:  AKT signaling pathway.                               
Pathway map shows all genes involved in the AKT signaling pathway as well as marking genes 
involved in pathway that were significantly up or down regulated in our data.  The map was 
generated by uploading the microarray data (combined data set for all 6 patients) into GeneGo
Software for pathway analysis.  Thermometers indicate amount of differential gene expression for TI 
vs Leuk.  Red thermometers indicate level of up-regulation, blue thermometers indicate level of 
down-regulation.  AKT is a critical regulator of DC lifespan, and over-expression of AKT has been 





What distinguishes ECP from nearly all other selective cancer immunotherapies 
has been its clinical success in a significant subpopulation of patients.  This success led to 
an expedited approval by the FDA for the treatment of CTCL, making ECP the first 
selective immunotherapy approved by the FDA for cancer.  The high response rates in 
immunocompetent CTCL patients (113) have promoted widespread use of this therapy, 
not only in CTCL but also other serious T cell mediated diseases.  ECP has been 
administered in more than 150 centers worldwide more than 250,000 times (1).  It is 
effective and safe, with no limiting toxicity and remarkably few adverse reactions (2).  
This therapy is already currently available at a large percentage of leading tertiary care 
centers in the USA and Europe, making it easy to initiate treatment as well as large-scale 
clinical trials.  Despite these significant successes, the fact remains that ECP has not 
achieved a universal acceptance in the world of cancer immunotherapy.    
 
A likely reason for the hesitation by many cancer immunotherapists to embrace 
ECP is the fact that the clinical successes preceded a mechanistic understanding of this 
therapy.  However in 2001, a potential mechanism for the mysterious efficacy of CTCL 
was elucidated (11) and subsequently used to rationally modify ECP, leading to the 
introduction of Transimmunization (TI) (12, 24).  TI was conceived under the simple 
premise that the most efficient means for facilitating cell-to-cell contact between newly 
formed DC and newly apoptotic malignant cells was to incubate them together overnight 
(11).  In conventional ECP, monocytes, which are activated by the treatment procedure, 
become DC after their return to the patient and malignant cells, rendered apoptotic by 
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exposure to 8-MOP + UVA, undergo apoptosis after their return to the patient.  These 
two cell populations must encounter each other in the body post reinfusion.  This is likely 
to occur in areas of sequestration of lymphoid cells, such as the spleen and lymph nodes, 
making these associations more likely.  The efficacy of ECP, which is dependent on the 
interaction of DC and apoptotic cells, speaks to the incredible ability of our immune 
system to amplify a few key cellular events into a systemic immune response.   
 
TI is an exciting and unique immunotherapy in that it has the same excellent 
safety profile as ECP, but is potentially more potent in terms of producing anti-tumor 
immune responses, since CTCL patients that were non-responsive to ECP improved 
clinically after TI therapy (24).  The key cellular events that take place in TI are the same 
as those in ECP: apoptosis of the passaged lymphocytes, and activation of monocytes.  
Although seemingly simple, the intricacies of these cellular events contribute to the 
remarkable efficacy of these immunotherapies.  For instance, the 8-MOP +UVA induced 
apoptosis of malignant lymphocytes is entirely unique in the field of cancer as a method 
of inducing apoptosis, since the activity of 8-MOP can be turned on and off with a light 
switch.  When activated for just millionths of a second by long wave (low energy) 
ultraviolet light, 8-MOP forms cross-links in DNA (29).  Through adjusting both the 
concentration of the drug and the intensity of UVA light, one can tightly focus the impact 
of the drug (29).  Because it is biologically inert and safe in its inactivated form, 8-MOP 
is one of the most titratable potent drugs in clinical use.  During the development of ECP, 
it was decided to use the lowest possible dose of 8-MOP, to avoid large-scale apoptosis 
and tumor lysis syndrome.  In retrospect the lower dose of 8-MOP, which causes a more 
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gradual apoptosis, likely contributes to the ability of tumor antigens to be recognized by 
DC and successfully presented to cytotoxic CD8 T cells.  The malignant cells are not 
blown to bits, but rather undergo a slower cell death, increasing the likelihood that 
surface proteins (tumor antigens) will remain intact.   
 
The other key cellular event in both ECP and TI is the activation of the monocyte 
population.  Monocytes are resistant to apoptosis induced by 8-MOP + UVA and 
maintain their ability to bind to plastic (10).  Our group has previously published work 
demonstrating that large numbers of monocytes become activated after ECP, and 
following overnight incubation of ECP treated cells (TI), these monocytes progress 
further to develop within one day into actively phagocytic cells that express markers 
associated with the transition into the DC pathway (11).  We showed that the 
differentiating DC were avidly phagocytic and engulfed apoptotic malignant T cells.  The 
results of these prior studies suggested that TI induces tumor-loaded dendritic cells 
capable of modulating immune responses.   
 
We set out to more fully characterize TI-induced DC and gain insight into their 
mechanism of induction.  Our goal was to determine the gene expression pattern of TI-
induced DC.  We studied the effects of TI on the monocyte/DC population in CTCL and 
GVHD patients as well as in healthy normal individuals, in order to gain insight into 




We sought to identify gene expression changes that occur during TI in order to 
more fully characterize TI-induced DC.  Genes known to be involved in DC 
differentiation and maturation were differentially expressed after TI.  Our results were in 
agreement with studies performed looking at gene expression changes in human 
monocyte-derived dendritic cells which were generated by culture for 5 days with GM-
CSF + IL-4 followed by stimulation with LPS for 2 days, as well as DC generated by 
GM-CSF + IL-4 for 7 days followed by TNFalpha for an additional 7 days (30, 39).  
After our 24 hour TI procedure, we saw up-regulation of genes encoding DC-LAMP, 
CCR7, CD83, CD86, and MHC class I that were noted by others only after culturing 
monocytes for 7-14 days with cytokines.  In addition to significant up-regulation of 
highly specific markers for mature DC, we also saw up-regulation of genes known to 
play an important role in DC function, such as the co-stimulatory molecule CD80 (B7-1, 
co-stimulatory signal for T cells) and the transcription factor NFkB, which controls the 
expression of numerous genes involved in inflammatory immune responses (115).  The 
fact that TI induces gene expression changes associated with mature, activated dendritic 
cells in 24 hours is important since groups using more conventional methods of 
producing mature DC do not see these gene expression changes until the cells have been 
cultured for at least a week (30, 39).  This data indicates that TI rapidly induces mature 
DC, and because the safety and efficacy of these DC have already been proven clinically, 
TI may represent a particularly valuable form of immunotherapy. 
 
Considering the cellular events that occur during TI and their relevance to 
physiologic DC maturation, it may not be entirely surprising that TI is capable of 
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inducing such rapid DC maturation.  In vivo, monocytes continuously emigrate from the 
blood into peripheral tissues.  The process of migration across endothelial cell layers has 
been proposed to initiate monocyte to DC differentiation, with cell adhesion playing a 
crucial role (116).  When migration and cell adhesion take place in the presence of 
phagocytic stimuli (such as apoptotic cells), a stronger maturation stimulus results, with 
DC reaching full maturity at an accelerated rate (116).  The results of our pathway 
analysis, which showed that the chemokine and cell adhesion pathway is significantly 
involved in TI, indicate that cell adhesion may play a crucial role in the mechanism of 
Transimmunization.  Because of the repetitive adhesion and disadhesion to the plastic 
treatment plate, it is likely that these physiologic signaling cascades initiated by adhesion 
are amplified, producing a strong maturation signal.  This cell adhesion occurs in the 
presence of many potential “danger signals”, which are also a crucial part of physiologic 
DC maturation.  The presence of apoptotic lymphocytes may also provide an additional 
maturation stimulus (117).   
 
Our data suggest that TI is capable of inducing a gene expression profile 
consistent with DC maturity regardless of disease state.  Similar up-regulations of DC 
maturity genes were observed in CTCL, GVHD, and healthy normal controls. In addition 
to finding that TI leads to the up-regulation of genes specific for mature DC, we also 
found that the majority (60%) of genes that were differentially expressed after TI were 
the same in both CTCL and GVHD patients.  This result is particularly interesting 
because ECP, the therapy upon which TI is based, causes much different immune 
responses in these two patient groups.  ECP is thought to stimulate an anti-tumor 
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cytotoxic CD8 T cell response in CTCL patients, whereas, in GVHD, ECP is thought to 
selectively suppress the lymphocytes producing the graft-versus-host reaction (22).  Our 
data showing up-regulation both of some genes associated with the ability to stimulate 
and others with the ability to suppress immune responses in both patient populations does 
not clarify the situation.  For instance, the gene encoding indoleamine, a protein 
associated T cell suppression (53), is significantly up-regulated in both CTCL and GVHD 
patients after TI.  However, the interleukin 1 receptor gene, which plays an important role 
in activating NFkB and mediating the inflammatory response (118), is also up-regulated 
in both patient populations after TI.   So does TI induce immunostimulatory or 
immunosuppressive DC?  The answer may in fact be that it is capable of inducing either 
kind of DC, depending on the environment in which the DC maturation process takes 
place.  Researchers in the field of immunology have established that DC which encounter 
antigen in the presence of “maturation” signals (inflammation) are activated, up-regulate 
co-stimulatory molecules and are capable of inducing T cell proliferation and 
inflammation.  DC which encounter antigen without inflammatory signals do not up-
regulate co-stimulatory molecules and are tolerogenic (23).  The advantage of TI is that 
the overnight culture system allows access to the newly differentiating DC and apoptotic 
cells, so adjuvant or cytokines could be added to the cell mixture to drive either 
immunostimulation or tolerance.  It is possible that we are inducing one population of DC 
that may be “multi-potential”, and because they express genes associated with both 
immunostimulation and immunosuppression, could be driven completely in one direction 
by the use of cytokines or adjuvant.  Another possibility is that that we are inducing two 
separate populations of DC, one which is immunostimulatory and the other which is 
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immunosuppressive.  Further studies are warranted to determine if there are multiple DC 
populations being induced.  Alternatively, it is possible that from the start DC precursors 
from CTCL and GVHD patients have a different “genetic program” that has developed as 
a result of their environment.  TI may act on these distinct sets of DC precursors in 
different ways, so that despite many genes being up-regulated in common, the cells still 
function differently in vivo.  It is important to mention that in addition to the commonly 
differentially expressed genes there were many genes unique to CTCL and GVHD 
patients and perhaps these unique genes may provide clues about the pre-existing 
“genetic program” of these DC precursors.  The most important message that can be 
derived from our gene expression data is that TI induces a mature gene expression profile 
and that these DC up-regulate genes associated with the ability to modulate immune 
responses.  Characterization of the function of TI-induced DC is crucial and these 
experiments are currently underway in our laboratory.   
 
Further characterization of TI’s unique ability to induce DC maturation included 
an analysis of significantly involved signaling pathways.  The results of this analysis 
suggest that two major groups of signaling pathways are involved: those associated with 
apoptosis and cell survival, and those associated with chemokines, cell adhesion, and the 
immune response.  According to the GeneGo pathway description, the major apoptosis-
related pathway, the apoptotic TNF-family pathway, is activated in response to DNA 
damage stimulus.  There is also significant involvement of a pathway involved in 
regulation of the cell cycle (ATM/ATR regulation of G1/S checkpoint), described by 
GeneGo as a “DNA damage checkpoint and response to DNA damage stimulus”.  
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Considering that cells undergoing TI are subjected to 8-MOP+UVA, which is known to 
cause DNA damage, it makes sense that these pathways are activated.  However, 
previous studies have shown that the monocyte population is resistant to 8-MOP+UVA 
induced apoptosis (10).  The involvement of several pro-survival pathways could provide 
an explanation for this.  There are three pro-survival pathways that are significantly 
involved in ECP: the anti-apoptotic TNFs/NFkB/Bcl-2 pathway, the AKT signaling 
pathway, and the anti-apoptotic TNFs/NFkB/IAP pathway.  The AKT signaling pathway 
is of particular interest because it is known to play a role in mediating DC survival (111).  
AKT is not only a critical regulator of DC lifespan; its activation is also thought to 
contribute to an enhanced ability of DC to stimulate T cell proliferation, activation, and 
long-term memory responses (111).   Cancer immunologists have suggested that 
promoting activation of AKT can improve the clinical efficacy of DC-based tumor 
vaccines (111).   The other major group of pathways involved in TI are the chemokines, 
cell adhesion, and the immune response pathways.  The involvement of the chemokines 
and adhesion pathway in both ECP and TI supports the theory that adhesion to the plastic 
UVA exposure plate during ECP plays an important role in the mechanism of these 
therapies, likely activating monocytes and initiating DC differentiation.  The involvement 
of the alternative complement pathway is interesting, as this pathway is associated with 
inflammatory immune responses.  Also, the significant involvement of signaling 
mediated by IL-6 and IL-1 suggests TI-induced DC are up-regulating signaling cascades 




One of the benefits of microarray gene expression studies is that they produce 
large amounts of data and allow for analysis of overall patterns of gene expression.  
However, sometimes the sheer quantity of the data makes it difficult to navigate and 
therefore it can be helpful to have a focus while analyzing the data.  We chose to focus on 
changes in gene expression that occurred in both CTCL and GVHD patients because this 
group represented the majority of differentially expressed genes after TI and contained 
many important DC and immune response related genes.  However, upon initial analysis 
of the genes that are uniquely expressed in either CTCL or GVHD patients, it is clear that 
these genes may hold important clues to the mechanism of TI in these two patient groups.  
For instance, the marked up-regulation of heat shock proteins in CTCL patients could 
play an important role in the generation of the anti-tumor immune response (119).  Heat 
shock protein 70, which is up-regulated in CTCL patients only after TI, plays a crucial 
role in cross-priming and the generation of antigen-specific cytotoxic T cell responses 
(119).  In GVHD patients only, there was up-regulation of IL-19 and tryptophan 2,3 
dioxygenase (TDO2).  IL-19 is a transcriptional activator of IL-10, an 
immunosuppressive cytokine that has been implicated in the mechanism of ECP in 
GVHD patients (120).  TDO2 is an enzyme closely related to indoleamine, and a recently 
published report suggests that indoleamine may play a protective role in GVHD, 
diminishing inflammation and disease severity (121).  The up-regulation of a natural 
killer (NK) cell receptor gene in CTCL patients and the down-regulation of three NK 
receptor genes in GVHD patients likely represents changes in expression occurring in NK 
cells since these cells were in the population from which we isolated the RNA.  The 
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generation of NK cells in CTCL would be desirable since they are capable of mediating 
potent anti-tumor cytotoxic responses (122).   
 
TI was designed with the goal of improving the efficacy of ECP for the treatment 
of cancer.  Because fully mature dendritic cells are more potent stimulators of CD8 T cell 
responses than immature DC (123), the fact that TI is capable of inducing mature DC in 
an efficient manner makes it ideal for this purpose.  TI has been tested clinically in cancer 
patients with CTCL with impressive clinical results (24).  As more is learned about TI 
and its underlying mechanism its uses may expand, but at the outset this treatment will be 
tested and optimized as a DC-based cancer immunotherapy.  Improved immunotherapies 
are desperately needed for cancer patients, and with its ability to generate large numbers 
of mature DC Transimmunization holds great promise as a cancer immunotherapy.   
  
The clinical successes of ECP and TI stand in stark contrast to the disappointing 
clinical findings of other forms of DC-based tumor vaccines.  In melanoma, for which 
there has been the greatest number of DC-based tumor vaccine trials, the cumulative 
clinical response rate for Phase I/II studies of dendritic cell-based therapeutic vaccines is 
14% (124).  A greater response rate of 21% was achieved in a study using anti-CTLA4 in 
combination with a melanoma peptide-based vaccine, however 43% of patients showed 
grade III-IV autoimmune toxicities (125).  This high level of autoimmune toxicity is 
concerning and contrary to the goal of immunotherapy, which is to provide targeted 
therapy with minimal toxicity.  In prostate cancer, the clinical results of phase I and II 
studies of DC-based vaccines show a response rate ranging between 10-46% (126).  A 
phase III clinical trial is currently underway to assess Dendreon’s sipuleucel-T vaccine, 
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which uses autologous antigen-presenting cells loaded with a conjugate protein.  This 
therapy holds some promise in terms of increasing survival although the clinical trials to 
date have not demonstrated an increase in time to disease progression (127).  In head and 
neck cancer vaccine-based approaches have achieved limited success, with a peptide-
based vaccine currently being evaluated in a phase I clinical trial (128).  In colorectal 
cancer, a tumor-lysate-loaded DC vaccine was unable to induce long-lasting effective 
immune responses in patients (129).  Researchers in ovarian cancer, frustrated with the 
failures of current strategies to induce significant anti-tumor immunity, have focused on 
overcoming tumor-mediated immune subversion through depleting T regulatory cells, 
although the clinical efficacy of this approach has not yet been tested (130).  In general, 
the clinical efficacy of cancer vaccines has been surprisingly low, with an average 
objective response rate of 3.8% in patients with metastatic cancers (131).  Many 
researchers feel these treatment strategies will not be widely adapted until their clinical 
efficacy is improved (132).   
 
A targeted DC-based cancer immunotherapy with proven clinical efficacy may 
already exist in Transimmunization.  This work demonstrates that Transimmunization 
induces a gene expression profile consistent with mature DC.  Dr. Berger and colleagues 
have previously shown that these DC are loaded with apoptotic malignant cells, 
suggesting that during the process of TI-driven monocyte to DC differentiation the newly 
differentiating DC pass through an aggressively phagocytic stage, in which they can 
become loaded with tumor antigens (11).  TI therefore represents an attractive strategy 
for the treatment of a multitude of different cancers, even solid tumors.  If tumor cells 
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were harvested and rendered apoptotic, either by 8-MOP + UVA treatment or another 
method, they could be incubated overnight with a patient’s TI treated cells.  The newly 
differentiating DC could phagocytose the tumor cells and become loaded with tumor 
antigen before reinfusion into the patient the following day.  This method circumvents the 
complex issues surrounding identification of specific tumor antigens and loading DC 
with these antigens.  Whole tumor cells, expressing the full array of tumor antigens in 
that particular patient, could be used to load TI-induced DC with a diverse set of patient-
specific tumor antigens.  This is a particularly elegant design because the best antigens to 
target for anti-tumor vaccines for most cancers have not truly been defined (133) and may 
be unique to an individual patient’s tumor (134). 
 
The concept of using apoptotic whole tumor cells as a source of antigen for cancer 
immunotherapy is embraced by world-renowned DC biologists such as Jacque 
Banchereau (119).  Dr. Banchereau’s group and others have shown that ex-vivo-
generated DCs loaded with killed tumor cells can generate clinical responses in cancer 
patients (119).  Recently, this group reported that treating tumor cells with hyperthermia 
enhances cross priming of tumor-specific CTLs, likely via up-regulation of HSP70 (135).  
Hyperthermia is used because it stresses the tumor cells and up-regulates heat shock 
proteins, which play important roles in activating DC (135).  In relating this to ECP, it is 
conceivable that ECP may be a type of stress treatment for CTCL cells.  We saw up-
regulation of heat shock proteins, signs of cellular stress, in CTCL patients.  However, we 
do not know if heat shock proteins were specifically up-regulated in the malignant CD4+ 
cells because we depleted this cell population.  Although we did not analyze the gene 
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expression in the CD4+ population in this current study, all of the CD4+ fractions 
isolated from the patient samples have been saved in archival storage and it would be 
interesting to go back and look at heat shock expression levels in these samples.   
 
There are several characteristics of TI-induced DC that make TI a particularly 
appealing immunotherapy for cancer.  First, TI generates mature DC in 24 hours, making 
it an extremely efficient method for producing mature DC.  Because the induction of a 
mature DC phenotype occurs so rapidly, these DC are relatively synchronized in terms of 
their maturational state.  Dr. Carole Berger has calculated that each TI treatment 
procedure induces approximately 350 million synchronized, mature DC (personal 
communication, Dr. Carole Berger, data not shown).  This number was generated using 
the white blood count of normal control donors, and multiplying it by the percentage of 
monocytes and then the percentage of CD83+ monocytes induced by TI.  Because mature 
DC are known to be superior generators of T cell responses (124), it is highly desirable to 
generate large numbers of these cells, all at the same maturation point.  Second, TI-
induces DC by a more physiologic mechanism than conventional culture methods, which 
involve at least a week in cell culture and flood monocytes with extremely high, non-
physiologic concentrations of exogenous cytokines.  In TI, cell adhesion pathways are 
activated in the presence of phagocytic stimuli and likely also danger signals released 
from apoptotic cells, mimicking physiologic circumstances under which monocytes 
undergo activation and differentiation into DC (116).  Third, TI generates highly 
personalized and specific antigen-loaded DC for each patient.  This therapy starts with a 
patient’s own monocytes, and as these cells differentiate into DC they phagocytose the 
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patient’s own tumor cells, allowing for the full array of tumor antigens in that patient to 
be presented.  Finally, TI has proven clinical efficacy, making it unique in the field of 
cancer immunotherapy.  TI is safe and readily available, as ECP treatment centers already 
exist around the world and minimal additional materials are necessary to perform the 
overnight incubation step.   
 
TI has tremendous potential as a treatment for various immunogenic cancers.  
While TI has thus far only been performed on cancer patients, TI’s precursor, ECP, is 
used not only for cancer treatment but also for the treatment of T-cell mediated immune 
diseases such as GVHD.  TI may generate mature DC that could be modulated through 
the addition of exogenous agents to be inducers of tolerance, thus expanding the possible 
uses of TI.  The ability to control the type of immune response induced may be provided 
by the access to all the constituents of the immune response present in the treatment 
culture bag. 
 
The survival rate for many cancers remains frustratingly low, despite the 
dedication and long history of high-quality basic and clinical science in the field of 
cancer research.  Immunotherapy for cancer is appealing because it has the potential to 
generate specific anti-tumor immune responses with little systemic toxicity.  However, 
the current state of cancer immunotherapy, particularly in the area of DC-based tumor 
vaccines, is disappointing.  Transimmunization is an ideal method for the generation of 
tumor-antigen loaded, mature DC with the ability to induce systemic anti-tumor immune 
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responses.  Our hope is that the full potential of this powerful and unique immunotherapy 
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